Interações de Olmesartana + anlodipino + hidroclorotiazida

Because of the hydrochlorothiazide component, olmesartan medoxomil, amlodipine and hydrochlorothiazide tablet is contraindicated in patients with anuria, hypersensitivity to any component, or hypersensitivity to other sulfonamide-derived drugs. (bula de Olmesartana + anlodipino + hidroclorotiazida, Contraindicações)

CONTRAINDICATIONS All diuretics, including ethacrynic acid, are contraindicated in anuria. (bula de Ácido etacrínico, Contraindicações)

Because the use of diuretics can accentuate the diminished intravascular volume, avoid diuretics except in the late phase of resolution. (bula de Alfacoriogonadotropina, Advertências)

Do not co-administer aliskiren with olmesartan medoxomil, amlodipine and hydrochlorothiazide tablet in patients with diabetes [ See Drug Interactions (7.2)]. (bula de Olmesartana + anlodipino + hidroclorotiazida, Contraindicações)

Hyperkalemia occurs commonly (about 10%) when amiloride is used without a kaliuretic diuretic. (bula de Amilorida, Advertência em caixa preta)

Do not coadminister aliskiren with angiotensin receptor blockers (ARBs), angiotensin-converting enzyme (ACE) inhibitors, including amlodipine and benazepril hydrochloride capsules in patients with diabetes. (bula de Anlodipino + benazepril, Contraindicações)

Do not coadminister aliskiren with angiotensin receptor blockers, ACE inhibitors, including Lotensin in patients with diabetes [see Drug Interactions (7.4) ] . (bula de Benazepril, Contraindicações)

Lotensin HCT is also contraindicated in patients who are hypersensitive to benazepril, to any other ACE inhibitor, to hydrochlorothiazide, or to other sulfonamide-derived drugs. (bula de Benazepril + hidroclorotiazida, Contraindicações)

Literature reports suggest that oral calcium antagonists may be used in combination with beta-adrenergic blocking agents when heart function is normal, but should be avoided in patients with impaired cardiac function. (bula de Betaxolol, Interações medicamentosas)

Sodium bicarbonate injection is contraindicated in patients who are losing chloride by vomiting or from continuous gastrointestinal suction and in patients receiving diuretics known to produce a hypochloremic alkalosis. (bula de Bicarbonato de sódio, Contraindicações)

Because of the hydrochlorothiazide component, olmesartan medoxomil, amlodipine and hydrochlorothiazide tablet is contraindicated in patients with anuria, hypersensitivity to any component, or hypersensitivity to other sulfonamide-derived drugs. (bula de Olmesartana + anlodipino + hidroclorotiazida, Contraindicações)

WARNING Bumetanide is a potent diuretic which, if given in excessive amounts, can lead to a profound diuresis with water and electrolyte depletion. (bula de Bumetanida, Advertência em caixa preta)

Potassium-Sparing Diuretics Cyclosporine should not be used with potassium-sparing diuretics because hyperkalemia can occur. (bula de Ciclosporina, Interações medicamentosas)

The following drug interactions may occur with potassium citrate: Potassium-sparing diuretics: concomitant administration should be avoided since the simultaneous administration of these agents can produce severe hyperkalemia (7.1) (bula de Citrato de potássio, Interações medicamentosas)

Table 2: Oral drugs that can be administered concomitantly with Ferric Citrate Tablets Amlodipine Aspirin Atorvastatin Calcitriol Clopidogrel Digoxin Diltiazem Doxercalciferol Enalapril Fluvastatin Glimepiride Levofloxacin Losartan Metoprolol Pravastatin Propranolol Sitagliptin Warfarin Oral drugs that have to be separated from Ferric Citrate Tablets and meals… (bula de Citrato férrico, Interações medicamentosas)

…with colchicine; markedly increased transaminases with lomitapide; rhabdomyolysis with simvastatin, lovastatin, and atorvastatin; hypoglycemia and cardiac arrhythmias (e.g., torsades de pointes) with disopyramide; and hypotension and acute kidney injury with calcium channel blockers metabolized by CYP3A4 (e.g., verapamil, amlodipine, diltiazem, nifedipine). (bula de Claritromicina, Advertências e precauções)

• Calcium Channel Blockers: Avoid concomitant use with Calcium Chloride Injection. (bula de Cloreto de cálcio, Interações medicamentosas)

Use CLOZARIL cautiously in patients with cardiovascular or cerebrovascular disease or conditions predisposing to hypotension (e.g., dehydration, use of antihypertensive medications) [see Dosage and Administration ( 2.2 , 2.6 ), Warnings and Precautions ( 5.2 )]. (bula de Clozapina, Advertência em caixa preta)

The concomitant use of RYANODEX and calcium channel blockers is not recommended during the treatment of malignant hyperthermia. (bula de Dantroleno, Interações medicamentosas)

CONTRAINDICATIONS PROGLYCEM is contraindicated in patients with: Functional hypoglycemia Hypersensitivity to diazoxide, any of the excipients in PROGLYCEM, or other thiazides (bula de Diazóxido, Contraindicações)

Because of the hydrochlorothiazide component, olmesartan medoxomil, amlodipine and hydrochlorothiazide tablet is contraindicated in patients with anuria, hypersensitivity to any component, or hypersensitivity to other sulfonamide-derived drugs. (bula de Olmesartana + anlodipino + hidroclorotiazida, Contraindicações)

The concomitant use of hydrochlorothiazide (alone or in combinations such as with triamterene) with dofetilide is contraindicated (see PRECAUTIONS, Drug-Drug Interactions ) because this has been shown to significantly increase dofetilide plasma concentrations and QT interval prolongation. (bula de Dofetilida, Contraindicações)

Because of the hydrochlorothiazide component, olmesartan medoxomil, amlodipine and hydrochlorothiazide tablet is contraindicated in patients with anuria, hypersensitivity to any component, or hypersensitivity to other sulfonamide-derived drugs. (bula de Olmesartana + anlodipino + hidroclorotiazida, Contraindicações)

Because of the hydrochlorothiazide component, olmesartan medoxomil, amlodipine and hydrochlorothiazide tablet is contraindicated in patients with anuria, hypersensitivity to any component, or hypersensitivity to other sulfonamide-derived drugs. (bula de Olmesartana + anlodipino + hidroclorotiazida, Contraindicações)

Droperidol should be administered with extreme caution to patients who may be at risk for development of prolonged QT syndrome (e.g., congestive heart failure, bradycardia, use of a diuretic, cardiac hypertrophy, hypokalemia, hypomagnesemia, or administration of other drugs known to increase the QT interval). (bula de Droperidol, Advertência em caixa preta)

…sometimes associated with oliguria and/or progressive azotemia, and rarely with acute renal failure and/or death, include those with the following conditions or characteristics: heart failure, hyponatremia, high dose diuretic therapy, recent intensive diuresis or increase in diuretic dose, renal dialysis, or severe volume and/or salt depletion of any etiology. (bula de Enalaprilate, Advertências)

…• serum creatinine > 2.0 mg/dL in males or >1.8 mg/dL in females, • creatinine clearance < 50 mL/min, or • concomitant administration of potassium supplements or potassium-sparing diuretics (e.g., amiloride, spironolactone, or triamterene) [see Warnings and Precautions (5.1) , Adverse Reactions (6.2) , Drug Interactions (7) , and Clinical Pharmacology (12.3)… (bula de Eplerenona, Contraindicações)

…of active abnormal bleeding within the previous 30 days Severe hypertension (systolic blood pressure >200 mm Hg or diastolic blood pressure >110 mm Hg) not adequately controlled on antihypertensive therapy Major surgery within the preceding 6 weeks History of stroke within 30 days or any history of hemorrhagic stroke Current or planned administration of another… (bula de Eptifibatida, Contraindicações)

IV administration of cardiodepressant calcium-channel antagonists (e.g., verapamil) and BREVIBLOC in close proximity (i.e., while cardiac effects from the other are still present); fatal cardiac arrests have occurred in patients receiving BREVIBLOC and intravenous verapamil. (bula de Esmolol, Contraindicações)

Because the use of diuretics can accentuate the diminished intravascular volume, diuretics should be avoided except in the late phase of resolution as described below. (bula de Folitropina, Advertências e precauções)

The concurrent use of gentamicin with potent diuretics, such as ethacrynic acid or furosemide, should be avoided, since certain diuretics by themselves may cause ototoxicity. (bula de Gentamicina, Advertência em caixa preta)

Avoid diuretics or laxatives in patients with diarrhea. (bula de Irinotecano, Advertências e precauções)

Calcium Channel Blockers Felodipine Nisoldipine Contraindicated during and 2 weeks after TOLSURA treatment. (bula de Itraconazol, Interações medicamentosas)

IV administration of non-dihydropyridine calcium-channel antagonists (e.g., verapamil) Hypersensitivity reactions, including anaphylaxis, to labetalol Bronchial asthma ( 4 ) (bula de Labetalol, Contraindicações)

Because of the hydrochlorothiazide component, olmesartan medoxomil, amlodipine and hydrochlorothiazide tablet is contraindicated in patients with anuria, hypersensitivity to any component, or hypersensitivity to other sulfonamide-derived drugs. (bula de Olmesartana + anlodipino + hidroclorotiazida, Contraindicações)

Other Antihypertensive Drugs When metolazone tablets, USP, are used with other antihypertensive drugs, particular care must be taken to avoid excessive reduction of blood pressure, especially during initial therapy. (bula de Metolazona, Advertências)

Minoxidil should be reserved for hypertensive patients who do not respond adequately to maximum therapeutic doses of a diuretic and two other antihypertensive agents. (bula de Minoxidil, Advertência em caixa preta)

The concurrent use of neomycin with potent diuretics such as ethacrynic acid or furosemide should be avoided, since certain diuretics by themselves may cause ototoxicity. (bula de Neomicina, Advertência em caixa preta)

Esses medicamentos reduzem a excreção de potássio; acrescentar suplementos de potássio ou substitutos do sal pode causar hipercalemia, que afeta o ritmo cardíaco. (NIH Office of Dietary Supplements, Potassium)

…sometimes associated with oliguria and/or progressive azotemia, and rarely with acute renal failure and/or death, include patients with the following conditions or characteristics: heart failure, hyponatremia, high dose diuretic therapy, recent intensive diuresis or increase in diuretic dose, renal dialysis, or severe volume and/or salt depletion of any etiology. (bula de Quinapril, Advertências)

Because of the hydrochlorothiazide component, olmesartan medoxomil, amlodipine and hydrochlorothiazide tablet is contraindicated in patients with anuria, hypersensitivity to any component, or hypersensitivity to other sulfonamide-derived drugs. (bula de Olmesartana + anlodipino + hidroclorotiazida, Contraindicações)

Because of the hydrochlorothiazide component, olmesartan medoxomil, amlodipine and hydrochlorothiazide tablet is contraindicated in patients with anuria, hypersensitivity to any component, or hypersensitivity to other sulfonamide-derived drugs. (bula de Olmesartana + anlodipino + hidroclorotiazida, Contraindicações)

Because of the hydrochlorothiazide component, olmesartan medoxomil, amlodipine and hydrochlorothiazide tablet is contraindicated in patients with anuria, hypersensitivity to any component, or hypersensitivity to other sulfonamide-derived drugs. (bula de Olmesartana + anlodipino + hidroclorotiazida, Contraindicações)

Because of the hydrochlorothiazide component, olmesartan medoxomil, amlodipine and hydrochlorothiazide tablet is contraindicated in patients with anuria, hypersensitivity to any component, or hypersensitivity to other sulfonamide-derived drugs. (bula de Olmesartana + anlodipino + hidroclorotiazida, Contraindicações)

…coadministration of an alpha-blocker and CIALIS for the treatment of BPH has not been adequately studied, and due to the potential vasodilatory effects of combined use resulting in blood pressure lowering, the combination of CIALIS and alpha-blockers is not recommended for the treatment of BPH. [see Dosage and Administration ( 2.7 ), Drug Interactions ( 7.1 ),… (bula de Tadalafila, Advertências e precauções)

The risk of torsade de pointes is related to the extent of QTc prolongation, concomitant administration of QTc prolonging drugs, a history of torsade de pointes, pre-existing QTc interval prolongation, congestive heart failure, administration of potassium-wasting diuretics, or other conditions that result in hypokalemia or hypomagnesemia. (bula de Trióxido de arsênio, Advertências e precauções)

Because of the hydrochlorothiazide component, olmesartan medoxomil, amlodipine and hydrochlorothiazide tablet is contraindicated in patients with anuria, hypersensitivity to any component, or hypersensitivity to other sulfonamide-derived drugs. (bula de Olmesartana + anlodipino + hidroclorotiazida, Contraindicações)

Immunosuppressants: Amlodipine may increase the systemic exposure of cyclosporine or tacrolimus when co-administered. (bula de Olmesartana + anlodipino + hidroclorotiazida, Interações medicamentosas)

Immunosuppressants: Amlodipine may increase the systemic exposure of cyclosporine or tacrolimus when co-administered. (bula de Olmesartana + anlodipino + hidroclorotiazida, Interações medicamentosas)

• Increased amlodipine exposure when coadministered with CYP3A inhibitors Hydrochlorothiazide ( 7.3 ): • Antidiabetic drugs: Dosage adjustment of antidiabetic may be required. (bula de Olmesartana + anlodipino + hidroclorotiazida, Interações medicamentosas)

Although β-blockers should be avoided in overt cardiac failure, acebutolol can be used with caution in patients with a history of heart failure who are controlled with digitalis and/or diuretics. (bula de Acebutolol, Advertências)

Olmesartan medoxomil ( 7.1 ): • Nonsteroidal anti-inflammatory drugs (NSAIDS): May lead to increased risk of renal impairment and loss of antihypertensive effect. (bula de Olmesartana + anlodipino + hidroclorotiazida, Interações medicamentosas)

Olmesartan medoxomil ( 7.1 ): • Nonsteroidal anti-inflammatory drugs (NSAIDS): May lead to increased risk of renal impairment and loss of antihypertensive effect. (bula de Olmesartana + anlodipino + hidroclorotiazida, Interações medicamentosas)

Olmesartan medoxomil ( 7.1 ): • Nonsteroidal anti-inflammatory drugs (NSAIDS): May lead to increased risk of renal impairment and loss of antihypertensive effect. (bula de Olmesartana + anlodipino + hidroclorotiazida, Interações medicamentosas)

Elderly patients and those receiving diuretic therapy are at increased risk of acute renal failure. (bula de Ácido zoledrônico, Advertências e precauções)

Immunosuppressants: Amlodipine may increase the systemic exposure of cyclosporine or tacrolimus when co-administered. (bula de Olmesartana + anlodipino + hidroclorotiazida, Interações medicamentosas)

Immunosuppressants: Amlodipine may increase the systemic exposure of cyclosporine or tacrolimus when co-administered. (bula de Olmesartana + anlodipino + hidroclorotiazida, Interações medicamentosas)

Following initiation and titration of Epogen, approximately 25% of patients on dialysis required initiation of or increases in antihypertensive therapy; hypertensive encephalopathy and seizures have been reported in patients with CKD receiving Epogen. (bula de Alfaepoetina, Advertências e precauções)

Postural hypotension/syncope: Care should be taken in patients with symptomatic hypotension or who have had a hypotensive response to other medications or are concomitantly treated with antihypertensive medication or nitrates ( 5.1 ) (bula de Alfuzosina, Advertências e precauções)

• Increased amlodipine exposure when coadministered with CYP3A inhibitors Hydrochlorothiazide ( 7.3 ): • Antidiabetic drugs: Dosage adjustment of antidiabetic may be required. (bula de Olmesartana + anlodipino + hidroclorotiazida, Interações medicamentosas)

• Increased amlodipine exposure when coadministered with CYP3A inhibitors Hydrochlorothiazide ( 7.3 ): • Antidiabetic drugs: Dosage adjustment of antidiabetic may be required. (bula de Olmesartana + anlodipino + hidroclorotiazida, Interações medicamentosas)

Hypersensitivity reactions to allopurinol tablets may be increased in patients with decreased kidney function receiving thiazide diuretics and allopurinol tablets concurrently. (bula de Alopurinol, Advertências e precauções)

Ethacrynic Acid, Furosemide, Urea, or Mannitol Some diuretics can enhance aminoglycoside toxicity by altering aminoglycoside concentrations in serum and tissue. (bula de Amicacina, Interações medicamentosas)

• Increased amlodipine exposure when coadministered with CYP3A inhibitors Hydrochlorothiazide ( 7.3 ): • Antidiabetic drugs: Dosage adjustment of antidiabetic may be required. (bula de Olmesartana + anlodipino + hidroclorotiazida, Interações medicamentosas)

Risk factors for developing acute angle-closure glaucoma may include a history of sulfonamide or penicillin allergy. (bula de Olmesartana + anlodipino + hidroclorotiazida, Advertências e precauções)

Risk factors for developing acute angle-closure glaucoma may include a history of sulfonamide or penicillin allergy. (bula de Olmesartana + anlodipino + hidroclorotiazida, Advertências e precauções)

Risk factors for developing acute angle-closure glaucoma may include a history of sulfonamide or penicillin allergy. (bula de Olmesartana + anlodipino + hidroclorotiazida, Advertências e precauções)

Risk factors for developing acute angle-closure glaucoma may include a history of sulfonamide or penicillin allergy. (bula de Olmesartana + anlodipino + hidroclorotiazida, Advertências e precauções)

The pressor effects of diethylpropion and those of other drugs may be additive when the drugs are used concomitantly; conversely, diethylpropion may interfere with antihypertensive drugs (i.e., guanethidine, a-methyldopa). (bula de Anfepramona (dietilpropiona), Interações medicamentosas)

Impact of Other Drugs on Amlodipine CYP3A Inhibitors Co-administration with CYP3A inhibitors (moderate and strong) results in increased systemic exposure to amlodipine and may require dose reduction. (bula de Anlodipino, Interações medicamentosas)

• Myopathy and Rhabdomyolysis: Risk factors include age 65 years or greater, uncontrolled hypothyroidism, renal impairment, concomitant use with certain other drugs, and higher amlodipine and atorvastatin dosage. (bula de Anlodipino + atorvastatina, Advertências e precauções)

In patients with an activated renin-angiotensin system, such as volume and/or salt-depleted patients (e.g., those being treated with high doses of diuretics) symptomatic hypotension may be anticipated after initiation of treatment with olmesartan medoxomil . (bula de Anlodipino + olmesartana, Advertências e precauções)

In patients with an activated renin-angiotensin system, such as volume- and/or salt-depleted patients receiving high doses of diuretics, symptomatic hypotension may occur in patients receiving angiotensin receptor blockers. (bula de Anlodipino + valsartana, Advertências e precauções)

• Increased amlodipine exposure when coadministered with CYP3A inhibitors Hydrochlorothiazide ( 7.3 ): • Antidiabetic drugs: Dosage adjustment of antidiabetic may be required. (bula de Olmesartana + anlodipino + hidroclorotiazida, Interações medicamentosas)

Xanthine derivatives, steroids, diuretics, or non-potassium sparing diuretics may potentiate hypokalemia or ECG changes. (bula de Arformoterol, Interações medicamentosas)

Antihypertensive Drugs Due to its alpha-adrenergic antagonism, aripiprazole has the potential to enhance the effect of certain antihypertensive agents. (bula de Aripiprazol, Interações medicamentosas)

Blood pressure should be closely monitored when amlodipine is co-administered with CYP3A inducers. (bula de Olmesartana + anlodipino + hidroclorotiazida, Interações medicamentosas)

Orthostatic vital signs should be monitored in patients who are vulnerable to hypotension (elderly patients, patients with dehydration, hypovolemia, concomitant treatment with antihypertensive medications, patients with known cardiovascular disease (history of myocardial infarction or ischemic heart disease, heart failure, or conduction abnormalities), and patients… (bula de Asenapina, Advertências e precauções)

• Increased amlodipine exposure when coadministered with CYP3A inhibitors Hydrochlorothiazide ( 7.3 ): • Antidiabetic drugs: Dosage adjustment of antidiabetic may be required. (bula de Olmesartana + anlodipino + hidroclorotiazida, Interações medicamentosas)

(See DOSAGE AND ADMINISTRATION . ) Concomitant Use of Calcium Channel Blockers Bradycardia and heart block can occur and the left ventricular end diastolic pressure can rise when beta-blockers are administered with verapamil or diltiazem. (bula de Atenolol, Advertências)

Because of its relative beta 1 -selectivity, however, atenolol and chlorthalidone may be used with caution in patients with bronchospastic disease who do not respond to or cannot tolerate, other antihypertensive treatment. (bula de Atenolol + clortalidona, Advertências)

Antihypertensive Drugs Prevention or Management Increase the frequency of monitoring blood pressure and adjust atomoxetine oral solution dosage as clinically appropriate. (bula de Atomoxetina, Interações medicamentosas)

CYP3A4 Substrate When administered with avanafil 200 mg, amlodipine (5 mg daily) increased the C max and AUC of avanafil by approximately 22% and 70%, respectively. (bula de Avanafila, Interações medicamentosas)

Immunosuppressants: Amlodipine may increase the systemic exposure of cyclosporine or tacrolimus when co-administered. (bula de Olmesartana + anlodipino + hidroclorotiazida, Interações medicamentosas)

Hypotension in Volume- or Salt-Depleted Patients In patients with an activated renin-angiotensin system, such as volume- and/or salt-depleted patients (e.g., those being treated with high doses of diuretics), symptomatic hypotension may occur after initiation of treatment with azilsartan medoxomil. (bula de Azilsartana, Advertências e precauções)

Immunosuppressants: Amlodipine may increase the systemic exposure of cyclosporine or tacrolimus when co-administered. (bula de Olmesartana + anlodipino + hidroclorotiazida, Interações medicamentosas)

Diuretics Clinical Impact : Opioids can reduce the efficacy of diuretics by inducing the release of antidiuretic hormone. (bula de Beladona + ópio, Interações medicamentosas)

Amphetamines may decrease the hypotensive effect of antihypertensives. (bula de Benzfetamina, Interações medicamentosas)

Risk factors for developing acute angle-closure glaucoma may include a history of sulfonamide or penicillin allergy. (bula de Olmesartana + anlodipino + hidroclorotiazida, Advertências e precauções)

• Increased amlodipine exposure when coadministered with CYP3A inhibitors Hydrochlorothiazide ( 7.3 ): • Antidiabetic drugs: Dosage adjustment of antidiabetic may be required. (bula de Olmesartana + anlodipino + hidroclorotiazida, Interações medicamentosas)

Because of its relative beta 1 -selectivity, however, BISOPROLOL FUMARATE may be used with caution in patients with bronchospastic disease who do not respond to, or who cannot tolerate other antihypertensive treatment. (bula de Bisoprolol, Advertências)

Because of the relative beta 1 -selectivity of bisoprolol fumarate, bisoprolol fumarate and hydrochlorothiazide tablets may be used with caution in patients with bronchospastic disease who do not respond to, or who cannot tolerate other antihypertensive treatment. (bula de Bisoprolol + hidroclorotiazida, Advertências)

Hypotension: Use caution when treating patients taking antihypertensives, with a history of syncope, or with dehydration. (bula de Bortezomibe, Advertências e precauções)

Blood pressure should be closely monitored when amlodipine is co-administered with CYP3A inducers. (bula de Olmesartana + anlodipino + hidroclorotiazida, Interações medicamentosas)

Orthostatic vital signs should be monitored in patients who are vulnerable to hypotension (e.g., elderly patients, patients with dehydration, hypovolemia, concomitant treatment with antihypertensive medication), patients with known cardiovascular disease (history of myocardial infarction, ischemic heart disease, heart failure, or conduction abnormalities), and… (bula de Brexpiprazol, Advertências e precauções)

Antihypertensives/Cardiac Glycosides Because brimonidine tartrate ophthalmic solution 0.1% and 0.15% may reduce blood pressure, caution in using drugs such as antihypertensives and/or cardiac glycosides with brimonidine tartrate ophthalmic solution 0.1% and 0.15% is advised. (bula de Brimonidina, Interações medicamentosas)

Oral or intravenous calcium antagonists may cause atrioventricular conduction disturbances, left ventricular failure, and hypotension. (bula de Brimonidina + timolol, Interações medicamentosas)

Use caution in patients taking antihypertensive medications. (bula de Bromocriptina, Advertências e precauções)

Central Nervous System (CNS) depressants Antihistamines have additive effects with alcohol and other CNS depressants (hypnotics, sedatives, tranquilizers, antianxiety agents, etc.). Antihypertensive drugs Sympathomimetic may reduce the effects of antihypertensive drugs. (bula de Bronfeniramina + pseudoefedrina + dextrometorfano, Interações medicamentosas)

Diuretics: Use with caution. (bula de Budesonida + formoterol, Interações medicamentosas)

Examples: cyclobenzaprine, metaxalone Diuretics Clinical Impact: Opioids can reduce the efficacy of diuretics by inducing the release of antidiuretic hormone. (bula de Buprenorfina, Interações medicamentosas)

Examples: Cyclobenzaprine, metaxalone Diuretics Clinical Impact: Opioids can reduce the efficacy of diuretics by inducing the release of antidiuretic hormone. (bula de Buprenorfina + naloxona, Interações medicamentosas)

Olmesartan medoxomil ( 7.1 ): • Nonsteroidal anti-inflammatory drugs (NSAIDS): May lead to increased risk of renal impairment and loss of antihypertensive effect. (bula de Olmesartana + anlodipino + hidroclorotiazida, Interações medicamentosas)

Olmesartan medoxomil ( 7.1 ): • Nonsteroidal anti-inflammatory drugs (NSAIDS): May lead to increased risk of renal impairment and loss of antihypertensive effect. (bula de Olmesartana + anlodipino + hidroclorotiazida, Interações medicamentosas)

Examples: cyclobenzaprine, metaxalone Diuretics Clinical Impact: Opioids can reduce the efficacy of diuretics by inducing the release of antidiuretic hormone. (bula de Butalbital + paracetamol + cafeína + codeína, Interações medicamentosas)

Thiazides Thiazides are known to induce hypercalcemia by the reduction of calcium excretion in urine. (bula de Calcitriol, Interações medicamentosas)

• Increased amlodipine exposure when coadministered with CYP3A inhibitors Hydrochlorothiazide ( 7.3 ): • Antidiabetic drugs: Dosage adjustment of antidiabetic may be required. (bula de Olmesartana + anlodipino + hidroclorotiazida, Interações medicamentosas)

Symptomatic hypotension is most likely to occur in patients who have been volume and/or salt depleted as a result of prolonged diuretic therapy, dietary salt restriction, dialysis, diarrhea, or vomiting. (bula de Candesartana, Advertências e precauções)

In studies of ACE inhibitors in patients with unilateral or bilateral renal artery stenosis, increases in serum creatinine or blood urea nitrogen (BUN) have been reported. (bula de Olmesartana + anlodipino + hidroclorotiazida, Advertências e precauções)

Blood pressure should be closely monitored when amlodipine is co-administered with CYP3A inducers. (bula de Olmesartana + anlodipino + hidroclorotiazida, Interações medicamentosas)

Symptomatic postural hypotension has occurred when carbidopa, given with levodopa or carbidopa-levodopa combination products, was added to the treatment of a patient receiving antihypertensive drugs. (bula de Carbidopa, Interações medicamentosas)

Antihypertensive drugs: May cause symptomatic postural hypotension. (bula de Carbidopa + levodopa, Interações medicamentosas)

Antihypertensive Agents Symptomatic postural hypotension has occurred when carbidopa/levodopa was added to the treatment of patients receiving antihypertensive drugs. (bula de Carbidopa + levodopa + entacapona, Interações medicamentosas)

Orthostatic vital signs should be monitored in patients who are vulnerable to hypotension (e.g., elderly patients, patients with dehydration, hypovolemia, and concomitant treatment with antihypertensive medications), patients with known cardiovascular disease (history of myocardial infarction, ischemic heart disease, heart failure, or conduction abnormalities), and… (bula de Cariprazina, Advertências e precauções)

If such symptoms occur, diuretics should be increased and the carvedilol dose should not be advanced until clinical stability resumes [see Dosage and Administration (2) ] . (bula de Carvedilol, Advertências e precauções)

Diuretics: Nephrotoxicity has been reported with concomitant administration of cephalosporins with potent diuretics such as furosemide. (bula de Cefepima, Interações medicamentosas)

Drug Interactions Nephrotoxicity has been reported following concomitant administration of cephalosporins with aminoglycoside antibacterial drugs or potent diuretics such as furosemide. (bula de Ceftazidima, Interações medicamentosas)

Olmesartan medoxomil ( 7.1 ): • Nonsteroidal anti-inflammatory drugs (NSAIDS): May lead to increased risk of renal impairment and loss of antihypertensive effect. (bula de Olmesartana + anlodipino + hidroclorotiazida, Interações medicamentosas)

• Increased amlodipine exposure when coadministered with CYP3A inhibitors Hydrochlorothiazide ( 7.3 ): • Antidiabetic drugs: Dosage adjustment of antidiabetic may be required. (bula de Olmesartana + anlodipino + hidroclorotiazida, Interações medicamentosas)

• Increased amlodipine exposure when coadministered with CYP3A inhibitors Hydrochlorothiazide ( 7.3 ): • Antidiabetic drugs: Dosage adjustment of antidiabetic may be required. (bula de Olmesartana + anlodipino + hidroclorotiazida, Interações medicamentosas)

Olmesartan medoxomil ( 7.1 ): • Nonsteroidal anti-inflammatory drugs (NSAIDS): May lead to increased risk of renal impairment and loss of antihypertensive effect. (bula de Olmesartana + anlodipino + hidroclorotiazida, Interações medicamentosas)

Olmesartan medoxomil ( 7.1 ): • Nonsteroidal anti-inflammatory drugs (NSAIDS): May lead to increased risk of renal impairment and loss of antihypertensive effect. (bula de Olmesartana + anlodipino + hidroclorotiazida, Interações medicamentosas)

…concomitant use of TONMYA with: MAO inhibitors may be life-threatening [see Contraindications (4) ] , Alcohol, barbiturates, and other CNS depressants may increase the risk of adverse reactions associated with these drugs, Tramadol may increase the seizure risk, Guanethidine or other similar acting drugs may block the antihypertensive action of these drugs. (bula de Ciclobenzaprina, Interações medicamentosas)

Immunosuppressants: Amlodipine may increase the systemic exposure of cyclosporine or tacrolimus when co-administered. (bula de Olmesartana + anlodipino + hidroclorotiazida, Interações medicamentosas)

Increase the dose of diuretics as needed [see Adverse Reactions (6) ] . (bula de Ciclossilicato de zircônio sódico, Advertências e precauções)

• Increased amlodipine exposure when coadministered with CYP3A inhibitors Hydrochlorothiazide ( 7.3 ): • Antidiabetic drugs: Dosage adjustment of antidiabetic may be required. (bula de Olmesartana + anlodipino + hidroclorotiazida, Interações medicamentosas)

Elderly patients, patients taking diuretics, and those who are volume depleted may be at greater risk for developing hyponatremia with SSRIs [see Use in Specific Populations ( 8.5 )] . (bula de Citalopram, Advertências e precauções)

Immunosuppressants: Amlodipine may increase the systemic exposure of cyclosporine or tacrolimus when co-administered. (bula de Olmesartana + anlodipino + hidroclorotiazida, Interações medicamentosas)

Blood pressure should be closely monitored when amlodipine is co-administered with CYP3A inducers. (bula de Olmesartana + anlodipino + hidroclorotiazida, Interações medicamentosas)

Consider use of diuretics and/or albumin. (bula de Clofarabina, Advertências e precauções)

Drugs that affect sinus node function or AV node conduction (e.g., digitalis, calcium channel blockers, beta blockers) Clinical Implication Concomitant use of drugs that affect sinus node function or AV node conduction with clonidine potentiate bradycardia and risk of AV block [see Warnings and Precautions (5.1) ]. (bula de Clonidina, Interações medicamentosas)

Thiazides may add to or potentiate the action of other antihypertensive drugs. (bula de Clorotiazida, Advertências)

Thiazide diuretics may accentuate the orthostatic hypotension that may occur with phenothiazines. (bula de Clorpromazina, Precauções)

Effect of chlorthalidone on other drugs Chlorthalidone may add to or potentiate the action of other antihypertensive drugs. (bula de Clortalidona, Interações medicamentosas)

Diuretics Clinical Impact: Opioids can reduce the efficacy of diuretics by inducing the release of antidiuretic hormone. (bula de Codeína, Interações medicamentosas)

• Colesevelam hydrochloride: Consider administering olmesartan at least 4 hours before colesevelam hydrochloride dose. (bula de Olmesartana + anlodipino + hidroclorotiazida, Interações medicamentosas)

• Cholestyramine and colestipol: Reduced absorption of thiazides. (bula de Olmesartana + anlodipino + hidroclorotiazida, Interações medicamentosas)

• Cholestyramine and colestipol: Reduced absorption of thiazides. (bula de Olmesartana + anlodipino + hidroclorotiazida, Interações medicamentosas)

• Increased amlodipine exposure when coadministered with CYP3A inhibitors Hydrochlorothiazide ( 7.3 ): • Antidiabetic drugs: Dosage adjustment of antidiabetic may be required. (bula de Olmesartana + anlodipino + hidroclorotiazida, Interações medicamentosas)

• Increased amlodipine exposure when coadministered with CYP3A inhibitors Hydrochlorothiazide ( 7.3 ): • Antidiabetic drugs: Dosage adjustment of antidiabetic may be required. (bula de Olmesartana + anlodipino + hidroclorotiazida, Interações medicamentosas)

• Increased amlodipine exposure when coadministered with CYP3A inhibitors Hydrochlorothiazide ( 7.3 ): • Antidiabetic drugs: Dosage adjustment of antidiabetic may be required. (bula de Olmesartana + anlodipino + hidroclorotiazida, Interações medicamentosas)

• Increased amlodipine exposure when coadministered with CYP3A inhibitors Hydrochlorothiazide ( 7.3 ): • Antidiabetic drugs: Dosage adjustment of antidiabetic may be required. (bula de Olmesartana + anlodipino + hidroclorotiazida, Interações medicamentosas)

Blood pressure should be closely monitored when amlodipine is co-administered with CYP3A inducers. (bula de Olmesartana + anlodipino + hidroclorotiazida, Interações medicamentosas)

Elderly patients, patients taking diuretics, and those who are volume-depleted may be at greater risk of developing hyponatremia with NORPRAMIN. (bula de Desipramina, Advertências)

…Hyponatremia Concomitant administration of DESMODA with other drugs that may increase the risk of water intoxication with hyponatremia, (e.g., tricyclic antidepressants, selective serotonin re-uptake inhibitors, chlorpromazine, opiate analgesics, thiazide diuretics, NSAIDs, lamotrigine, sulfonylureas, particularly chlorpropamide, oxybutynin and carbamazepine). (bula de Desmopressina, Interações medicamentosas)

Also, patients taking diuretics or who are otherwise volume depleted can be at greater risk [see Use in Specific Populations (8.5) and Clinical Pharmacology (12.3) ] . (bula de Desvenlafaxina, Advertências e precauções)

Blood pressure should be closely monitored when amlodipine is co-administered with CYP3A inducers. (bula de Olmesartana + anlodipino + hidroclorotiazida, Interações medicamentosas)

For patients expected to be on prolonged treatment or who take PPIs with medications such as digoxin or drugs that may cause hypomagnesemia (e.g., diuretics), health care professionals may consider monitoring magnesium levels prior to initiation of PPI treatment and periodically [see Adverse Reactions (6.2) ] . (bula de Dexlansoprazol, Advertências e precauções)

• Antihypertensive Drugs: Monitor blood pressure. (bula de Dexmetilfenidato, Interações medicamentosas)

Olmesartan medoxomil ( 7.1 ): • Nonsteroidal anti-inflammatory drugs (NSAIDS): May lead to increased risk of renal impairment and loss of antihypertensive effect. (bula de Olmesartana + anlodipino + hidroclorotiazida, Interações medicamentosas)

Olmesartan medoxomil ( 7.1 ): • Nonsteroidal anti-inflammatory drugs (NSAIDS): May lead to increased risk of renal impairment and loss of antihypertensive effect. (bula de Olmesartana + anlodipino + hidroclorotiazida, Interações medicamentosas)

Risk factors for developing acute angle-closure glaucoma may include a history of sulfonamide or penicillin allergy. (bula de Olmesartana + anlodipino + hidroclorotiazida, Advertências e precauções)

Olmesartan medoxomil ( 7.1 ): • Nonsteroidal anti-inflammatory drugs (NSAIDS): May lead to increased risk of renal impairment and loss of antihypertensive effect. (bula de Olmesartana + anlodipino + hidroclorotiazida, Interações medicamentosas)

Serum potassium levels should be carefully monitored when digoxin is given to patients at high risk of hypokalemia ( e.g. , those receiving diuretics, corticosteroids, or other drugs that commonly lead to potassium loss; those with gastrointestinal losses through diarrhea, vomiting, or nasogastric suction; or those with potassium-losing endocrinopathies or nephropathies). (bula de Digoxina, Advertências e precauções)

• Increased amlodipine exposure when coadministered with CYP3A inhibitors Hydrochlorothiazide ( 7.3 ): • Antidiabetic drugs: Dosage adjustment of antidiabetic may be required. (bula de Olmesartana + anlodipino + hidroclorotiazida, Interações medicamentosas)

Risk may be increased when used concomitantly with high dose calcium preparations, thiazide diuretics, or vitamin D compounds. (bula de Doxercalciferol, Advertências e precauções)

• Increased amlodipine exposure when coadministered with CYP3A inhibitors Hydrochlorothiazide ( 7.3 ): • Antidiabetic drugs: Dosage adjustment of antidiabetic may be required. (bula de Olmesartana + anlodipino + hidroclorotiazida, Interações medicamentosas)

Medications that may increase serum potassium concentration include ACE inhibitors, angiotensin-II receptor antagonists, potassium-sparing diuretics, potassium supplementation, heparin, aldosterone antagonists, and NSAIDS. (bula de Drospirenona + etinilestradiol, Advertências e precauções)

• Increased amlodipine exposure when coadministered with CYP3A inhibitors Hydrochlorothiazide ( 7.3 ): • Antidiabetic drugs: Dosage adjustment of antidiabetic may be required. (bula de Olmesartana + anlodipino + hidroclorotiazida, Interações medicamentosas)

The risk of BP decreases may be greater in patients taking concomitant medications that induce orthostatic hypotension (such as antihypertensives) or are potent CYP1A2 inhibitors [see Drug Interactions ( 7.1 )] and in patients taking duloxetine delayed-release capsules at doses above 60 mg daily. (bula de Duloxetina, Advertências e precauções)

Calcium Channel Antagonists Coadministration of verapamil or diltiazem decreases dutasteride clearance and leads to increased exposure to dutasteride. (bula de Dutasterida, Interações medicamentosas)

Calcium Channel Antagonists Dutasteride Coadministration of verapamil or diltiazem decreases dutasteride clearance and leads to increased exposure to dutasteride. (bula de Dutasterida + tansulosina, Interações medicamentosas)

• Increased amlodipine exposure when coadministered with CYP3A inhibitors Hydrochlorothiazide ( 7.3 ): • Antidiabetic drugs: Dosage adjustment of antidiabetic may be required. (bula de Olmesartana + anlodipino + hidroclorotiazida, Interações medicamentosas)

• Increased amlodipine exposure when coadministered with CYP3A inhibitors Hydrochlorothiazide ( 7.3 ): • Antidiabetic drugs: Dosage adjustment of antidiabetic may be required. (bula de Olmesartana + anlodipino + hidroclorotiazida, Interações medicamentosas)

Transporters Use caution when concomitantly administering ALVAIZ and drugs that are substrates of OATP1B1 (e.g., atorvastatin, bosentan, ezetimibe, fluvastatin, glyburide, olmesartan, pitavastatin, pravastatin, rosuvastatin, repaglinide, rifampin, simvastatin acid, SN-38 [active metabolite of irinotecan], valsartan) or breast cancer resistance protein (BCRP)… (bula de Eltrombopague, Interações medicamentosas)

• Increased amlodipine exposure when coadministered with CYP3A inhibitors Hydrochlorothiazide ( 7.3 ): • Antidiabetic drugs: Dosage adjustment of antidiabetic may be required. (bula de Olmesartana + anlodipino + hidroclorotiazida, Interações medicamentosas)

• Increased amlodipine exposure when coadministered with CYP3A inhibitors Hydrochlorothiazide ( 7.3 ): • Antidiabetic drugs: Dosage adjustment of antidiabetic may be required. (bula de Olmesartana + anlodipino + hidroclorotiazida, Interações medicamentosas)

• Increased amlodipine exposure when coadministered with CYP3A inhibitors Hydrochlorothiazide ( 7.3 ): • Antidiabetic drugs: Dosage adjustment of antidiabetic may be required. (bula de Olmesartana + anlodipino + hidroclorotiazida, Interações medicamentosas)

In studies of ACE inhibitors in patients with unilateral or bilateral renal artery stenosis, increases in serum creatinine or blood urea nitrogen (BUN) have been reported. (bula de Olmesartana + anlodipino + hidroclorotiazida, Advertências e precauções)

In studies of ACE inhibitors in patients with unilateral or bilateral renal artery stenosis, increases in serum creatinine or blood urea nitrogen (BUN) have been reported. (bula de Olmesartana + anlodipino + hidroclorotiazida, Advertências e precauções)

…Precautions (5.6) and Adverse Reactions (6) ]. β-blockers, such as propranolol Cyclopropane or halogenated hydrocarbon anesthetics, such as halothane Antihistamines Thyroid hormones Diuretics Cardiac glycosides, such as digitalis glycosides Quinidine Drugs potentiating hypokalemic effects of epinephrine • Potassium depleting diuretics • Corticosteroids • Theophylline… (bula de Epinefrina (adrenalina), Interações medicamentosas)

Additional reductions in blood pressure may occur when VELETRI is administered with diuretics, antihypertensive agents, or other vasodilators. (bula de Epoprostenol, Interações medicamentosas)

• Increased amlodipine exposure when coadministered with CYP3A inhibitors Hydrochlorothiazide ( 7.3 ): • Antidiabetic drugs: Dosage adjustment of antidiabetic may be required. (bula de Olmesartana + anlodipino + hidroclorotiazida, Interações medicamentosas)

Also, patients taking diuretics or who are otherwise volume depleted may be at greater risk. (bula de Escitalopram, Advertências e precauções)

Blood pressure should be closely monitored when amlodipine is co-administered with CYP3A inducers. (bula de Olmesartana + anlodipino + hidroclorotiazida, Interações medicamentosas)

For patients expected to be on prolonged treatment or who take PPIs with medications such as digoxin or drugs that may cause hypomagnesemia (e.g., diuretics), health care professionals may consider monitoring magnesium levels prior to initiation of PPI treatment and periodically [see Adverse Reactions (6.2) ] . (bula de Esomeprazol, Advertências e precauções)

In patients with an activated renin-angiotensin system, such as volume- and/or salt-depleted patients (e.g., those being treated with high doses of diuretics) symptomatic hypotension may be anticipated after initiation of treatment with olmesartan medoxomil. (bula de Olmesartana + anlodipino + hidroclorotiazida, Advertências e precauções)

In patients with an activated renin-angiotensin system, such as volume- and/or salt-depleted patients (e.g., those being treated with high doses of diuretics) symptomatic hypotension may be anticipated after initiation of treatment with olmesartan medoxomil. (bula de Olmesartana + anlodipino + hidroclorotiazida, Advertências e precauções)

Immunosuppressants: Amlodipine may increase the systemic exposure of cyclosporine or tacrolimus when co-administered. (bula de Olmesartana + anlodipino + hidroclorotiazida, Interações medicamentosas)

Olmesartan medoxomil ( 7.1 ): • Nonsteroidal anti-inflammatory drugs (NSAIDS): May lead to increased risk of renal impairment and loss of antihypertensive effect. (bula de Olmesartana + anlodipino + hidroclorotiazida, Interações medicamentosas)

Blood pressure should be closely monitored when amlodipine is co-administered with CYP3A inducers. (bula de Olmesartana + anlodipino + hidroclorotiazida, Interações medicamentosas)

• Increased amlodipine exposure when coadministered with CYP3A inhibitors Hydrochlorothiazide ( 7.3 ): • Antidiabetic drugs: Dosage adjustment of antidiabetic may be required. (bula de Olmesartana + anlodipino + hidroclorotiazida, Interações medicamentosas)

• Increased amlodipine exposure when coadministered with CYP3A inhibitors Hydrochlorothiazide ( 7.3 ): • Antidiabetic drugs: Dosage adjustment of antidiabetic may be required. (bula de Olmesartana + anlodipino + hidroclorotiazida, Interações medicamentosas)

Drug Interactions with Amlodipine Simvastatin: Co-administration of simvastatin with amlodipine increases the systemic exposure of simvastatin. (bula de Olmesartana + anlodipino + hidroclorotiazida, Interações medicamentosas)

…hydrochloride desipramine hydrochloride imipramine hydrochloride doxepin carbamazepine cyclobenzaprine HCl amoxapine maprotiline HCl trimipramine maleate protriptyline HCl mirtazapine Phenelzine sulfate should be used with caution in combination with antihypertensive drugs, including thiazide diuretics and β-blockers, since exaggerated hypotensive effects may result. (bula de Fenelzina, Advertências)

Antagonistic Effects (decrease in BIORPHEN blood pressure effect) can occur with α-adrenergic antagonists, phosphodiesterase Type 5 inhibitors, mixed α- and β-receptor antagonists, calcium channel blockers, benzodiazepines and ACE inhibitors, centrally acting sympatholytic agents. (bula de Fenilefrina, Interações medicamentosas)

Blood pressure should be closely monitored when amlodipine is co-administered with CYP3A inducers. (bula de Olmesartana + anlodipino + hidroclorotiazida, Interações medicamentosas)

Blood pressure should be closely monitored when amlodipine is co-administered with CYP3A inducers. (bula de Olmesartana + anlodipino + hidroclorotiazida, Interações medicamentosas)

Olmesartan medoxomil ( 7.1 ): • Nonsteroidal anti-inflammatory drugs (NSAIDS): May lead to increased risk of renal impairment and loss of antihypertensive effect. (bula de Olmesartana + anlodipino + hidroclorotiazida, Interações medicamentosas)

Risk factors for developing acute angle-closure glaucoma may include a history of sulfonamide or penicillin allergy. (bula de Olmesartana + anlodipino + hidroclorotiazida, Advertências e precauções)

…treatment with Class 1 and Class III antiarrhythmics, 4) treatment with monoamine oxidase inhibitors (MAOI's), 5) concomitant treatment with other drug products known to prolong the QT interval and 6) electrolyte imbalance, in particular hypokalemia and hypomagnesemia, or concomitant treatment with drugs (e.g., diuretics) that may cause electrolyte imbalance. (bula de Fentanila, Advertências e precauções)

Blood pressure should be closely monitored when amlodipine is co-administered with CYP3A inducers. (bula de Olmesartana + anlodipino + hidroclorotiazida, Interações medicamentosas)

Immunosuppressants: Amlodipine may increase the systemic exposure of cyclosporine or tacrolimus when co-administered. (bula de Olmesartana + anlodipino + hidroclorotiazida, Interações medicamentosas)

• Increased amlodipine exposure when coadministered with CYP3A inhibitors Hydrochlorothiazide ( 7.3 ): • Antidiabetic drugs: Dosage adjustment of antidiabetic may be required. (bula de Olmesartana + anlodipino + hidroclorotiazida, Interações medicamentosas)

Amphotericin B or potassium-depleting diuretics (benzothiadiazines and related drugs, ethacrynic acid and furosemide)—enhanced hypokalemia. (bula de Fludrocortisona, Interações medicamentosas)

Also, patients taking diuretics or who are otherwise volume depleted may be at greater risk [see Use in Specific Populations ( 8.5 )] . (bula de Fluoxetina, Advertências e precauções)

Olmesartan medoxomil ( 7.1 ): • Nonsteroidal anti-inflammatory drugs (NSAIDS): May lead to increased risk of renal impairment and loss of antihypertensive effect. (bula de Olmesartana + anlodipino + hidroclorotiazida, Interações medicamentosas)

Diuretics: Use with caution. (bula de Fluticasona + salmeterol, Interações medicamentosas)

Also, patients taking diuretics or who are otherwise volume depleted may be at greater risk. (bula de Fluvoxamina, Advertências e precauções)

• Xanthine derivatives, steroids, diuretics, or non-potassium sparing diuretics may potentiate hypokalemia or ECG changes. (bula de Formoterol, Interações medicamentosas)

• Increased amlodipine exposure when coadministered with CYP3A inhibitors Hydrochlorothiazide ( 7.3 ): • Antidiabetic drugs: Dosage adjustment of antidiabetic may be required. (bula de Olmesartana + anlodipino + hidroclorotiazida, Interações medicamentosas)

• Increased amlodipine exposure when coadministered with CYP3A inhibitors Hydrochlorothiazide ( 7.3 ): • Antidiabetic drugs: Dosage adjustment of antidiabetic may be required. (bula de Olmesartana + anlodipino + hidroclorotiazida, Interações medicamentosas)

When diuretics are indicated, thiazides are recommended over loop diuretics because the latter inhibit renal tubular secretion, and may impair elimination of FOSCAVIR, potentially leading to toxicity. (bula de Foscarnete, Interações medicamentosas)

Blood pressure should be closely monitored when amlodipine is co-administered with CYP3A inducers. (bula de Olmesartana + anlodipino + hidroclorotiazida, Interações medicamentosas)

In studies of ACE inhibitors in patients with unilateral or bilateral renal artery stenosis, increases in serum creatinine or blood urea nitrogen (BUN) have been reported. (bula de Olmesartana + anlodipino + hidroclorotiazida, Advertências e precauções)

In studies of ACE inhibitors in patients with unilateral or bilateral renal artery stenosis, increases in serum creatinine or blood urea nitrogen (BUN) have been reported. (bula de Olmesartana + anlodipino + hidroclorotiazida, Advertências e precauções)

Immunosuppressants: Amlodipine may increase the systemic exposure of cyclosporine or tacrolimus when co-administered. (bula de Olmesartana + anlodipino + hidroclorotiazida, Interações medicamentosas)

In patients with an activated renin-angiotensin system, such as volume- and/or salt-depleted patients (e.g., those being treated with high doses of diuretics) symptomatic hypotension may be anticipated after initiation of treatment with olmesartan medoxomil. (bula de Olmesartana + anlodipino + hidroclorotiazida, Advertências e precauções)

OATP1B1 substrates – Gemfibrozil is an inhibitor of organic anion-transporter polyprotein (OATP) 1B1 and may increase exposure of drugs that are substrates of OATP1B1 (e.g., atrasentan, atorvastatin, bosentan, ezetimibe, fluvastatin, glyburide, SN-38 [active metabolite of irinotecan], rosuvastatin, pitavastatin, pravastatin, rifampin, valsartan, olmesartan). (bula de Genfibrozila, Advertências)

• Increased amlodipine exposure when coadministered with CYP3A inhibitors Hydrochlorothiazide ( 7.3 ): • Antidiabetic drugs: Dosage adjustment of antidiabetic may be required. (bula de Olmesartana + anlodipino + hidroclorotiazida, Interações medicamentosas)

• Increased amlodipine exposure when coadministered with CYP3A inhibitors Hydrochlorothiazide ( 7.3 ): • Antidiabetic drugs: Dosage adjustment of antidiabetic may be required. (bula de Olmesartana + anlodipino + hidroclorotiazida, Interações medicamentosas)

Calcium Channel Blockers : Administration of calcium may reduce the response. (bula de Gliconato de cálcio, Interações medicamentosas)

• Increased amlodipine exposure when coadministered with CYP3A inhibitors Hydrochlorothiazide ( 7.3 ): • Antidiabetic drugs: Dosage adjustment of antidiabetic may be required. (bula de Olmesartana + anlodipino + hidroclorotiazida, Interações medicamentosas)

• Increased amlodipine exposure when coadministered with CYP3A inhibitors Hydrochlorothiazide ( 7.3 ): • Antidiabetic drugs: Dosage adjustment of antidiabetic may be required. (bula de Olmesartana + anlodipino + hidroclorotiazida, Interações medicamentosas)

• Increased amlodipine exposure when coadministered with CYP3A inhibitors Hydrochlorothiazide ( 7.3 ): • Antidiabetic drugs: Dosage adjustment of antidiabetic may be required. (bula de Olmesartana + anlodipino + hidroclorotiazida, Interações medicamentosas)

Blood pressure should be closely monitored when amlodipine is co-administered with CYP3A inducers. (bula de Olmesartana + anlodipino + hidroclorotiazida, Interações medicamentosas)

Immunosuppressants: Amlodipine may increase the systemic exposure of cyclosporine or tacrolimus when co-administered. (bula de Olmesartana + anlodipino + hidroclorotiazida, Interações medicamentosas)

Caution is advised when haloperidol decanoate is used in combination with drugs known to cause electrolyte imbalance (e.g., diuretics or corticosteroids) because hypokalemia, hypomagnesemia, and hypocalcemia are risk factors for QT prolongation. (bula de Haloperidol, Interações medicamentosas)

Example: Cyclobenzaprine, metaxalone Diuretics Clinical Impact: Opioids can reduce the efficacy of diuretics by inducing the release of antidiuretic hormone. (bula de Hidrocodona, Interações medicamentosas)

Diuretics : Hydrocodone may reduce the efficacy of diuretics. (bula de Hidrocodona + clorfeniramina, Interações medicamentosas)

Diuretics : Hydrocodone may reduce the efficacy of diuretics. (bula de Hidrocodona + homatropina, Interações medicamentosas)

Olmesartan medoxomil ( 7.1 ): • Nonsteroidal anti-inflammatory drugs (NSAIDS): May lead to increased risk of renal impairment and loss of antihypertensive effect. (bula de Olmesartana + anlodipino + hidroclorotiazida, Interações medicamentosas)

Diuretics Opioids can reduce the efficacy of diuretics by inducing the release of antidiuretic hormone. (bula de Hidrocodona + paracetamol, Interações medicamentosas)

Examples: cyclobenzaprine, metaxalone Diuretics Clinical Impact: Opioids can reduce the efficacy of diuretics by inducing the release of antidiuretic hormone. (bula de Hidromorfona, Interações medicamentosas)

Olmesartan medoxomil ( 7.1 ): • Nonsteroidal anti-inflammatory drugs (NSAIDS): May lead to increased risk of renal impairment and loss of antihypertensive effect. (bula de Olmesartana + anlodipino + hidroclorotiazida, Interações medicamentosas)

Olmesartan medoxomil ( 7.1 ): • Nonsteroidal anti-inflammatory drugs (NSAIDS): May lead to increased risk of renal impairment and loss of antihypertensive effect. (bula de Olmesartana + anlodipino + hidroclorotiazida, Interações medicamentosas)

Orthostatic vital signs should be monitored in patients who are vulnerable to hypotension (e.g., elderly patients, patients with dehydration, hypovolemia, and concomitant treatment with antihypertensive medications), patients with known cardiovascular disease (history of myocardial infarction, ischemic heart disease, heart failure, or conduction abnormalities), and… (bula de Iloperidona, Advertências e precauções)

• Increased amlodipine exposure when coadministered with CYP3A inhibitors Hydrochlorothiazide ( 7.3 ): • Antidiabetic drugs: Dosage adjustment of antidiabetic may be required. (bula de Olmesartana + anlodipino + hidroclorotiazida, Interações medicamentosas)

Elderly patients, patients taking diuretics, and those who are volume-depleted may be at greater risk of developing hyponatremia with imipramine hydrochloride tablets. (bula de Imipramina, Advertências)

Drug Interactions Other Antihypertensives: Indapamide may add to or potentiate the action of other antihypertensive drugs. (bula de Indapamida, Interações medicamentosas)

Olmesartan medoxomil ( 7.1 ): • Nonsteroidal anti-inflammatory drugs (NSAIDS): May lead to increased risk of renal impairment and loss of antihypertensive effect. (bula de Olmesartana + anlodipino + hidroclorotiazida, Interações medicamentosas)

Immunosuppressants: Amlodipine may increase the systemic exposure of cyclosporine or tacrolimus when co-administered. (bula de Olmesartana + anlodipino + hidroclorotiazida, Interações medicamentosas)

• Increased amlodipine exposure when coadministered with CYP3A inhibitors Hydrochlorothiazide ( 7.3 ): • Antidiabetic drugs: Dosage adjustment of antidiabetic may be required. (bula de Olmesartana + anlodipino + hidroclorotiazida, Interações medicamentosas)

• Increased amlodipine exposure when coadministered with CYP3A inhibitors Hydrochlorothiazide ( 7.3 ): • Antidiabetic drugs: Dosage adjustment of antidiabetic may be required. (bula de Olmesartana + anlodipino + hidroclorotiazida, Interações medicamentosas)

• Increased amlodipine exposure when coadministered with CYP3A inhibitors Hydrochlorothiazide ( 7.3 ): • Antidiabetic drugs: Dosage adjustment of antidiabetic may be required. (bula de Olmesartana + anlodipino + hidroclorotiazida, Interações medicamentosas)

• Increased amlodipine exposure when coadministered with CYP3A inhibitors Hydrochlorothiazide ( 7.3 ): • Antidiabetic drugs: Dosage adjustment of antidiabetic may be required. (bula de Olmesartana + anlodipino + hidroclorotiazida, Interações medicamentosas)

• Increased amlodipine exposure when coadministered with CYP3A inhibitors Hydrochlorothiazide ( 7.3 ): • Antidiabetic drugs: Dosage adjustment of antidiabetic may be required. (bula de Olmesartana + anlodipino + hidroclorotiazida, Interações medicamentosas)

• Increased amlodipine exposure when coadministered with CYP3A inhibitors Hydrochlorothiazide ( 7.3 ): • Antidiabetic drugs: Dosage adjustment of antidiabetic may be required. (bula de Olmesartana + anlodipino + hidroclorotiazida, Interações medicamentosas)

Concurrent use with potassium-containing medications, potassium-sparing diuretics and angiotensin-converting enzyme inhibitors (ACE inhibitors) may result in hyperkalemia and cardiac arrhythmias or cardiac arrest. (bula de Iodeto de potássio, Interações medicamentosas)

Diuretics The electrocardiogram (ECG) changes and/or hypokalemia that may result from the administration of non-potassium sparing diuretics (such as loop or thiazide diuretics) can be acutely worsened by β-agonists, especially when the recommended dose of the β-agonist is exceeded. (bula de Ipratrópio + salbutamol, Interações medicamentosas)

Hypotension in Volume or Salt-Depleted Patients In patients with an activated renin-angiotensin system, such as volume or salt-depleted patients (e.g., those being treated with high doses of diuretics), symptomatic hypotension may occur after initialization of treatment with AVAPRO. (bula de Irbesartana, Advertências e precauções)

Calcium Antagonists FORANE may lead to marked hypotension in patients treated with calcium antagonists. (bula de Isoflurano, Interações medicamentosas)

• Increased amlodipine exposure when coadministered with CYP3A inhibitors Hydrochlorothiazide ( 7.3 ): • Antidiabetic drugs: Dosage adjustment of antidiabetic may be required. (bula de Olmesartana + anlodipino + hidroclorotiazida, Interações medicamentosas)

• Increased amlodipine exposure when coadministered with CYP3A inhibitors Hydrochlorothiazide ( 7.3 ): • Antidiabetic drugs: Dosage adjustment of antidiabetic may be required. (bula de Olmesartana + anlodipino + hidroclorotiazida, Interações medicamentosas)

VIMPAT should also be used with caution in patients on concomitant medications that affect cardiac conduction, including sodium channel blockers, beta-blockers, calcium channel blockers, potassium channel blockers, and medications that prolong the PR interval [see Drug Interactions (7.2) ] . (bula de Lacosamida, Advertências e precauções)

For patients expected to be on prolonged treatment or who take PPIs with medications such as digoxin or drugs that may cause hypomagnesemia (e.g., diuretics), health care professionals may consider monitoring magnesium levels prior to initiation of PPI treatment and periodically [see Adverse Reactions (6.2) ] . (bula de Lansoprazol, Advertências e precauções)

Immunosuppressants: Amlodipine may increase the systemic exposure of cyclosporine or tacrolimus when co-administered. (bula de Olmesartana + anlodipino + hidroclorotiazida, Interações medicamentosas)

• Increased amlodipine exposure when coadministered with CYP3A inhibitors Hydrochlorothiazide ( 7.3 ): • Antidiabetic drugs: Dosage adjustment of antidiabetic may be required. (bula de Olmesartana + anlodipino + hidroclorotiazida, Interações medicamentosas)

Also, patients taking diuretics or who are otherwise volume depleted can be at greater risk. (bula de Levomilnaciprana, Advertências e precauções)

Diuretics Opioids can reduce the efficacy of diuretics by inducing the release of antidiuretic hormone. (bula de Levorfanol, Interações medicamentosas)

Diuretics The ECG changes or hypokalemia that may result from the administration of non-potassium-sparing diuretics (such as loop and thiazide diuretics) can be acutely worsened by beta-agonists, especially when the recommended dose of the beta-agonist is exceeded. (bula de Levossalbutamol, Interações medicamentosas)

• Increased amlodipine exposure when coadministered with CYP3A inhibitors Hydrochlorothiazide ( 7.3 ): • Antidiabetic drugs: Dosage adjustment of antidiabetic may be required. (bula de Olmesartana + anlodipino + hidroclorotiazida, Interações medicamentosas)

• Increased amlodipine exposure when coadministered with CYP3A inhibitors Hydrochlorothiazide ( 7.3 ): • Antidiabetic drugs: Dosage adjustment of antidiabetic may be required. (bula de Olmesartana + anlodipino + hidroclorotiazida, Interações medicamentosas)

Monitor serum sodium levels regularly in the elderly, in patients taking diuretics, and in other patients at risk of hyponatremia and/or SIADH while taking Linezolid injection. (bula de Linezolida, Advertências e precauções)

• Increased amlodipine exposure when coadministered with CYP3A inhibitors Hydrochlorothiazide ( 7.3 ): • Antidiabetic drugs: Dosage adjustment of antidiabetic may be required. (bula de Olmesartana + anlodipino + hidroclorotiazida, Interações medicamentosas)

In studies of ACE inhibitors in patients with unilateral or bilateral renal artery stenosis, increases in serum creatinine or blood urea nitrogen (BUN) have been reported. (bula de Olmesartana + anlodipino + hidroclorotiazida, Advertências e precauções)

In studies of ACE inhibitors in patients with unilateral or bilateral renal artery stenosis, increases in serum creatinine or blood urea nitrogen (BUN) have been reported. (bula de Olmesartana + anlodipino + hidroclorotiazida, Advertências e precauções)

• Lithium: Increases in serum lithium concentrations and lithium toxicity. (bula de Olmesartana + anlodipino + hidroclorotiazida, Interações medicamentosas)

Weak CYP3A4 Inhibitors Weak CYP3A4 inhibitors (such as alprazolam, amiodarone, amlodipine, atorvastatin, bicalutamide, cilostazol, cimetidine, cyclosporine, fluoxetine, fluvoxamine, ginkgo, goldenseal, isoniazid, lapatinib, nilotinib, pazopanib, ranitidine, ranolazine, ticagrelor, zileuton) can increase lomitapide exposure approximately 2-fold [see Clinical Pharmacology… (bula de Lomitapida, Interações medicamentosas)

• Increased amlodipine exposure when coadministered with CYP3A inhibitors Hydrochlorothiazide ( 7.3 ): • Antidiabetic drugs: Dosage adjustment of antidiabetic may be required. (bula de Olmesartana + anlodipino + hidroclorotiazida, Interações medicamentosas)

Blood pressure should be closely monitored when amlodipine is co-administered with CYP3A inducers. (bula de Olmesartana + anlodipino + hidroclorotiazida, Interações medicamentosas)

Hypotension in Volume- or Salt-Depleted Patients In patients with an activated renin-angiotensin system, such as volume- or salt-depleted patients (e.g., those being treated with high doses of diuretics), symptomatic hypotension may occur after initiation of treatment with COZAAR. (bula de Losartana, Advertências e precauções)

Orthostatic vital signs should be monitored in patients who are vulnerable to hypotension (e.g., elderly patients, patients with dehydration, hypovolemia, and concomitant treatment with antihypertensive drugs), patients with known cardiovascular disease (history of myocardial infarction, ischemic heart disease, heart failure, or conduction abnormalities), and patients… (bula de Lumateperona, Advertências e precauções)

Patients at increased risk of these adverse reactions or at increased risk of developing complications from hypotension include those with dehydration, hypovolemia, treatment with antihypertensive medication, history of cardiovascular disease (e.g., heart failure, myocardial infarction, ischemia, or conduction abnormalities), history of cerebrovascular disease,… (bula de Lurasidona, Advertências e precauções)

The action of Mecamylamine HCl may be potentiated by anesthesia, other antihypertensive drugs and alcohol. (bula de Mecamilamina, Interações medicamentosas)

Other Drugs that Prolong the QTc Interval Coadministration of other drugs known to alter cardiac conduction (e.g., anti-arrhythmic or beta-adrenergic blocking agents, calcium channel blockers, antihistamines or H 1 -blocking agents, tricyclic antidepressants and phenothiazines) might also contribute to a prolongation of the QTc interval. (bula de Mefloquina, Interações medicamentosas)

Olmesartan medoxomil ( 7.1 ): • Nonsteroidal anti-inflammatory drugs (NSAIDS): May lead to increased risk of renal impairment and loss of antihypertensive effect. (bula de Olmesartana + anlodipino + hidroclorotiazida, Interações medicamentosas)

Immunosuppressants: Amlodipine may increase the systemic exposure of cyclosporine or tacrolimus when co-administered. (bula de Olmesartana + anlodipino + hidroclorotiazida, Interações medicamentosas)

Closely monitor patients with risk factors for development of prolonged QT interval (e.g., cardiac hypertrophy, concomitant diuretic use, hypokalemia, hypomagnesemia), a history of cardiac conduction abnormalities, and those taking medications affecting cardiac conduction. (bula de Metadona, Advertências e precauções)

• Increased amlodipine exposure when coadministered with CYP3A inhibitors Hydrochlorothiazide ( 7.3 ): • Antidiabetic drugs: Dosage adjustment of antidiabetic may be required. (bula de Olmesartana + anlodipino + hidroclorotiazida, Interações medicamentosas)

Antihypertensive Drugs: Monitor blood pressure. (bula de Metilfenidato, Interações medicamentosas)

If such symptoms occur, increase diuretics and restore clinical stability before advancing the dose of Metoprolol Tartrate Tablets [see Dosage and Administration (2) ]. (bula de Metoprolol, Advertências e precauções)

Digitalis, Clonidine, and Calcium Channel Blockers: Digitalis glycosides, clonidine, diltiazem and verapamil slow atrioventricular conduction and decrease heart rate. (bula de Metoprolol + hidroclorotiazida, Interações medicamentosas)

Immunosuppressants: Amlodipine may increase the systemic exposure of cyclosporine or tacrolimus when co-administered. (bula de Olmesartana + anlodipino + hidroclorotiazida, Interações medicamentosas)

Immunosuppressants: Amlodipine may increase the systemic exposure of cyclosporine or tacrolimus when co-administered. (bula de Olmesartana + anlodipino + hidroclorotiazida, Interações medicamentosas)

• Increased amlodipine exposure when coadministered with CYP3A inhibitors Hydrochlorothiazide ( 7.3 ): • Antidiabetic drugs: Dosage adjustment of antidiabetic may be required. (bula de Olmesartana + anlodipino + hidroclorotiazida, Interações medicamentosas)

• Increased amlodipine exposure when coadministered with CYP3A inhibitors Hydrochlorothiazide ( 7.3 ): • Antidiabetic drugs: Dosage adjustment of antidiabetic may be required. (bula de Olmesartana + anlodipino + hidroclorotiazida, Interações medicamentosas)

Also, patients taking diuretics or who are otherwise volume-depleted may be at greater risk [see Geriatric Use ( 8.5 )] . (bula de Milnaciprana, Advertências e precauções)

• Increased amlodipine exposure when coadministered with CYP3A inhibitors Hydrochlorothiazide ( 7.3 ): • Antidiabetic drugs: Dosage adjustment of antidiabetic may be required. (bula de Olmesartana + anlodipino + hidroclorotiazida, Interações medicamentosas)

Elderly patients, patients taking diuretics, and those who are volume-depleted may be at greater risk of developing hyponatremia [see Use in Specific Populations (8.5) ] . (bula de Mirtazapina, Advertências e precauções)

Blood pressure should be closely monitored when amlodipine is co-administered with CYP3A inducers. (bula de Olmesartana + anlodipino + hidroclorotiazida, Interações medicamentosas)

Blood pressure should be closely monitored when amlodipine is co-administered with CYP3A inducers. (bula de Olmesartana + anlodipino + hidroclorotiazida, Interações medicamentosas)

Blood pressure should be closely monitored when amlodipine is co-administered with CYP3A inducers. (bula de Olmesartana + anlodipino + hidroclorotiazida, Interações medicamentosas)

In studies of ACE inhibitors in patients with unilateral or bilateral renal artery stenosis, increases in serum creatinine or blood urea nitrogen (BUN) have been reported. (bula de Olmesartana + anlodipino + hidroclorotiazida, Advertências e precauções)

Marked symptomatic orthostatic hypotension has been reported when calcium channel blockers and organic nitrates were used in combination. (bula de Mononitrato de isossorbida, Interações medicamentosas)

Diuretics Clinical Impact: Opioids can reduce the efficacy of diuretics by inducing the release of antidiuretic hormone. (bula de Morfina, Interações medicamentosas)

Olmesartan medoxomil ( 7.1 ): • Nonsteroidal anti-inflammatory drugs (NSAIDS): May lead to increased risk of renal impairment and loss of antihypertensive effect. (bula de Olmesartana + anlodipino + hidroclorotiazida, Interações medicamentosas)

Although beta-blockers should be avoided in overt congestive heart failure, if necessary, they can be used with caution in patients with a history of failure who are well-compensated, usually with digitalis and diuretics. (bula de Nadolol, Advertências)

Risk factors for developing acute angle-closure glaucoma may include a history of sulfonamide or penicillin allergy. (bula de Olmesartana + anlodipino + hidroclorotiazida, Advertências e precauções)

Diuretics Opioids can reduce the efficacy of diuretics by inducing the release of antidiuretic hormone. (bula de Nalbufina, Interações medicamentosas)

Olmesartan medoxomil ( 7.1 ): • Nonsteroidal anti-inflammatory drugs (NSAIDS): May lead to increased risk of renal impairment and loss of antihypertensive effect. (bula de Olmesartana + anlodipino + hidroclorotiazida, Interações medicamentosas)

Olmesartan medoxomil ( 7.1 ): • Nonsteroidal anti-inflammatory drugs (NSAIDS): May lead to increased risk of renal impairment and loss of antihypertensive effect. (bula de Olmesartana + anlodipino + hidroclorotiazida, Interações medicamentosas)

Immunosuppressants: Amlodipine may increase the systemic exposure of cyclosporine or tacrolimus when co-administered. (bula de Olmesartana + anlodipino + hidroclorotiazida, Interações medicamentosas)

• Increased amlodipine exposure when coadministered with CYP3A inhibitors Hydrochlorothiazide ( 7.3 ): • Antidiabetic drugs: Dosage adjustment of antidiabetic may be required. (bula de Olmesartana + anlodipino + hidroclorotiazida, Interações medicamentosas)

Non-dihydropyridine Calcium Channel Blockers Because of significant negative inotropic and chronotropic effects in patients treated with β-blockers and calcium channel blockers of the verapamil and diltiazem type, monitor the ECG and blood pressure in patients treated concomitantly with these agents. (bula de Nebivolol, Advertências e precauções)

• Increased amlodipine exposure when coadministered with CYP3A inhibitors Hydrochlorothiazide ( 7.3 ): • Antidiabetic drugs: Dosage adjustment of antidiabetic may be required. (bula de Olmesartana + anlodipino + hidroclorotiazida, Interações medicamentosas)

Blood pressure should be closely monitored when amlodipine is co-administered with CYP3A inducers. (bula de Olmesartana + anlodipino + hidroclorotiazida, Interações medicamentosas)

Caution should also be used when niacin extended-release tablets are used in patients with unstable angina or in the acute phase of an MI, particularly when such patients are also receiving vasoactive drugs such as nitrates, calcium channel blockers, or adrenergic blocking agents. (bula de Niacina (ácido nicotínico), Advertências e precauções)

Other Diuretics, PDE5 inhibitors, alpha-methyldopa: Nifedipine may increase the blood pressure lowering effect of these concomitantly administered agents. (bula de Nifedipino, Interações medicamentosas)

Blood Pressure Lowering Drugs Nimodipine may increase the blood pressure lowering effect of concomitantly administered anti-hypertensives such as diuretics, beta-blockers, ACE inhibitors, angiotensin receptor blockers, other calcium channel blockers, α-adrenergic blockers, PDE5 inhibitors, and α-methyldopa. (bula de Nimodipino, Interações medicamentosas)

• Increased amlodipine exposure when coadministered with CYP3A inhibitors Hydrochlorothiazide ( 7.3 ): • Antidiabetic drugs: Dosage adjustment of antidiabetic may be required. (bula de Olmesartana + anlodipino + hidroclorotiazida, Interações medicamentosas)

Antihypertensives: Possible additive hypotensive effects. (bula de Nitroglicerina, Interações medicamentosas)

Immunosuppressants: Amlodipine may increase the systemic exposure of cyclosporine or tacrolimus when co-administered. (bula de Olmesartana + anlodipino + hidroclorotiazida, Interações medicamentosas)

Beta Blocker and Calcium Channel Blockers : dose adjustment of beta blockers or calcium channel blockers may be necessary (‎ 7 ). (bula de Octreotida, Interações medicamentosas)

…of myocardial infarction or ischemia, heart failure, or conduction abnormalities), cerebrovascular disease, and conditions which would predispose patients to hypotension (dehydration, hypovolemia, and treatment with antihypertensive medications) where the occurrence of syncope, or hypotension and/or bradycardia might put the patient at increased medical risk. (bula de Olanzapina, Advertências e precauções)

…and fluoxetine capsules should be used with particular caution in patients with known cardiovascular disease (history of myocardial infarction or ischemia, heart failure, or conduction abnormalities), cerebrovascular disease, or conditions that would predispose patients to hypotension (dehydration, hypovolemia, and treatment with antihypertensive medications). (bula de Olanzapina + fluoxetina, Advertências e precauções)

Examples: cyclobenzaprine, metaxalone Diuretics Clinical Impact: Opioids can reduce the efficacy of diuretics by inducing the release of antidiuretic hormone. (bula de Oliceridina, Interações medicamentosas)

Hypotension in Volume- or Salt-Depleted Patients In patients with an activated renin-angiotensin-aldosterone system, such as volume- and/or salt-depleted patients (e.g., those being treated with high doses of diuretics), symptomatic hypotension may be anticipated after initiation of treatment with Benicar. (bula de Olmesartana, Advertências e precauções)

For patients expected to be on prolonged treatment or who take PPIs with medications such as digoxin or drugs that may cause hypomagnesemia (e.g., diuretics), health care professionals may consider monitoring magnesium levels prior to initiation of PPI treatment and periodically [see Adverse Reactions ( 6.2 )] . (bula de Omeprazol, Advertências e precauções)

For patients expected to be on prolonged treatment or who take PPIs with medications such as digoxin or drugs that may cause hypomagnesemia (e.g., diuretics), health care professionals may consider monitoring magnesium levels prior to initiation of PPI treatment and periodically [see Adverse Reactions ( 6.2 )] . (bula de Omeprazol + bicarbonato de sódio, Advertências e precauções)

Olmesartan medoxomil ( 7.1 ): • Nonsteroidal anti-inflammatory drugs (NSAIDS): May lead to increased risk of renal impairment and loss of antihypertensive effect. (bula de Olmesartana + anlodipino + hidroclorotiazida, Interações medicamentosas)

Risk factors for developing acute angle-closure glaucoma may include a history of sulfonamide or penicillin allergy. (bula de Olmesartana + anlodipino + hidroclorotiazida, Advertências e precauções)

Olmesartan medoxomil ( 7.1 ): • Nonsteroidal anti-inflammatory drugs (NSAIDS): May lead to increased risk of renal impairment and loss of antihypertensive effect. (bula de Olmesartana + anlodipino + hidroclorotiazida, Interações medicamentosas)

Blood pressure should be closely monitored when amlodipine is co-administered with CYP3A inducers. (bula de Olmesartana + anlodipino + hidroclorotiazida, Interações medicamentosas)

Examples: cyclobenzaprine, metaxalone Diuretics Clinical Impact: Opioids can reduce the efficacy of diuretics by inducing the release of antidiuretic hormone. (bula de Oxicodona, Interações medicamentosas)

Diuretics Clinical Impact: Opioids can reduce the efficacy of diuretics by inducing the release of antidiuretic hormone. (bula de Oxicodona + paracetamol, Interações medicamentosas)

Examples: butorphanol, nalbuphine, pentazocine, buprenorphine Diuretics Clinical Impact: Opioids can reduce the efficacy of diuretics by inducing the release of antidiuretic hormone. (bula de Oximorfona, Interações medicamentosas)

• Increased amlodipine exposure when coadministered with CYP3A inhibitors Hydrochlorothiazide ( 7.3 ): • Antidiabetic drugs: Dosage adjustment of antidiabetic may be required. (bula de Olmesartana + anlodipino + hidroclorotiazida, Interações medicamentosas)

Use ERZOFRI with caution in patients with known cardiovascular disease (e.g., heart failure, history of myocardial infarction or ischemia, conduction abnormalities), cerebrovascular disease, or conditions that predispose the patient to hypotension (e.g., dehydration, hypovolemia, and treatment with antihypertensive medications). (bula de Paliperidona, Advertências e precauções)

For patients expected to be on prolonged treatment or who take PPIs with medications such as digoxin or drugs that may cause hypomagnesemia (e.g., diuretics), health care professionals may consider monitoring magnesium levels prior to initiation of PPI treatment and periodically [see Adverse Reactions (6.2) ]. (bula de Pantoprazol, Advertências e precauções)

Diuretics Opioids can reduce the efficacy of diuretics by inducing the release of antidiuretic hormone. (bula de Paracetamol + codeína, Interações medicamentosas)

Olmesartan medoxomil ( 7.1 ): • Nonsteroidal anti-inflammatory drugs (NSAIDS): May lead to increased risk of renal impairment and loss of antihypertensive effect. (bula de Olmesartana + anlodipino + hidroclorotiazida, Interações medicamentosas)

The risk may be increased when Paricalcitol Injection is used concomitantly with high dose calcium preparations, thiazide diuretics, or vitamin D compounds. (bula de Paricalcitol, Advertências e precauções)

Elderly patients, patients taking diuretics, and those who are volume-depleted may be at greater risk of developing hyponatremia with SNRIs and SSRIs. [see Use in Specific Populations ( 8.5 )]. (bula de Paroxetina, Advertências e precauções)

Adjustments in the dose of drugs known to slow the heart rate (e.g., beta-blockers, calcium channel blockers) and correction of electrolyte disturbances may be necessary when initiating or during the course of SIGNIFOR LAR treatment. (bula de Pasireotida, Advertências e precauções)

Monitor blood pressure as clinically indicated and initiate and adjust antihypertensive therapy as appropriate. (bula de Pazopanibe, Advertências e precauções)

Diuretics Opioids can reduce the efficacy of diuretics by inducing the release of antidiuretic hormone. (bula de Pentazocina + naloxona, Interações medicamentosas)

Small decreases in blood pressure have been observed in some patients treated with pentoxifylline extended-release tablets; periodic systemic blood pressure monitoring is recommended for patients receiving concomitant antihypertensive therapy. (bula de Pentoxifilina, Interações medicamentosas)

• Increased amlodipine exposure when coadministered with CYP3A inhibitors Hydrochlorothiazide ( 7.3 ): • Antidiabetic drugs: Dosage adjustment of antidiabetic may be required. (bula de Olmesartana + anlodipino + hidroclorotiazida, Interações medicamentosas)

In studies of ACE inhibitors in patients with unilateral or bilateral renal artery stenosis, increases in serum creatinine or blood urea nitrogen (BUN) have been reported. (bula de Olmesartana + anlodipino + hidroclorotiazida, Advertências e precauções)

Examples: Cyclobenzaprine, metaxalone Diuretics Clinical Impact: Opioids can reduce the efficacy of diuretics by inducing the release of antidiuretic hormone. (bula de Petidina (meperidina), Interações medicamentosas)

Immunosuppressants: Amlodipine may increase the systemic exposure of cyclosporine or tacrolimus when co-administered. (bula de Olmesartana + anlodipino + hidroclorotiazida, Interações medicamentosas)

Although beta-blockers should be avoided in overt congestive heart failure, if necessary, pindolol tablets can be used with caution in patients with a history of failure who are well-compensated, usually with digitalis and diuretics. (bula de Pindolol, Advertências)

• Increased amlodipine exposure when coadministered with CYP3A inhibitors Hydrochlorothiazide ( 7.3 ): • Antidiabetic drugs: Dosage adjustment of antidiabetic may be required. (bula de Olmesartana + anlodipino + hidroclorotiazida, Interações medicamentosas)

• Increased amlodipine exposure when coadministered with CYP3A inhibitors Hydrochlorothiazide ( 7.3 ): • Antidiabetic drugs: Dosage adjustment of antidiabetic may be required. (bula de Olmesartana + anlodipino + hidroclorotiazida, Interações medicamentosas)

• Increased amlodipine exposure when coadministered with CYP3A inhibitors Hydrochlorothiazide ( 7.3 ): • Antidiabetic drugs: Dosage adjustment of antidiabetic may be required. (bula de Olmesartana + anlodipino + hidroclorotiazida, Interações medicamentosas)

Risk factors for developing acute angle-closure glaucoma may include a history of sulfonamide or penicillin allergy. (bula de Olmesartana + anlodipino + hidroclorotiazida, Advertências e precauções)

Olmesartan medoxomil ( 7.1 ): • Nonsteroidal anti-inflammatory drugs (NSAIDS): May lead to increased risk of renal impairment and loss of antihypertensive effect. (bula de Olmesartana + anlodipino + hidroclorotiazida, Interações medicamentosas)

Immunosuppressants: Amlodipine may increase the systemic exposure of cyclosporine or tacrolimus when co-administered. (bula de Olmesartana + anlodipino + hidroclorotiazida, Interações medicamentosas)

• Increased amlodipine exposure when coadministered with CYP3A inhibitors Hydrochlorothiazide ( 7.3 ): • Antidiabetic drugs: Dosage adjustment of antidiabetic may be required. (bula de Olmesartana + anlodipino + hidroclorotiazida, Interações medicamentosas)

Syncopal episodes have usually occurred within 30 to 90 minutes of the initial dose of the drug; occasionally, they have been reported in association with rapid dosage increases or the introduction of another antihypertensive drug into the regimen of a patient taking high doses of prazosin hydrochloride capsules. (bula de Prazosina, Advertências)

Blood pressure should be closely monitored when amlodipine is co-administered with CYP3A inducers. (bula de Olmesartana + anlodipino + hidroclorotiazida, Interações medicamentosas)

Thiazide diuretics may accentuate the orthostatic hypotension that may occur with phenothiazines. (bula de Proclorperazina, Precauções)

Diuretics : Codeine may reduce the efficacy of diuretics. (bula de Prometazina + codeína, Interações medicamentosas)

The concomitant use of beta-adrenergic blockers and non-dihydropyridine calcium channel blockers (e.g., verapamil and diltiazem), digoxin or clonidine increases the risk of significant bradycardia. (bula de Propranolol, Advertências e precauções)

Quetiapine should be used with particular caution in patients with known cardiovascular disease (history of myocardial infarction or ischemic heart disease, heart failure, or conduction abnormalities), cerebrovascular disease, or conditions which would predispose patients to hypotension (dehydration, hypovolemia, and treatment with antihypertensive medications). (bula de Quetiapina, Advertências e precauções)

In studies of ACE inhibitors in patients with unilateral or bilateral renal artery stenosis, increases in serum creatinine or blood urea nitrogen (BUN) have been reported. (bula de Olmesartana + anlodipino + hidroclorotiazida, Advertências e precauções)

Drugs that alkalinize the urine ( carbonic-anhydrase inhibitors, sodium bicarbonate, thiazide diuretics ) reduce renal elimination of quinidine. (bula de Quinidina, Interações medicamentosas)

For patients expected to be on prolonged treatment or who take PPIs with medications such as digoxin or drugs that may cause hypomagnesemia (e.g., diuretics), health care professionals may consider monitoring magnesium levels prior to initiation of PPI treatment and periodically [see Adverse Reactions (6.2) ]. (bula de Rabeprazol, Advertências e precauções)

In studies of ACE inhibitors in patients with unilateral or bilateral renal artery stenosis, increases in serum creatinine or blood urea nitrogen (BUN) have been reported. (bula de Olmesartana + anlodipino + hidroclorotiazida, Advertências e precauções)

• Increased amlodipine exposure when coadministered with CYP3A inhibitors Hydrochlorothiazide ( 7.3 ): • Antidiabetic drugs: Dosage adjustment of antidiabetic may be required. (bula de Olmesartana + anlodipino + hidroclorotiazida, Interações medicamentosas)

• Increased amlodipine exposure when coadministered with CYP3A inhibitors Hydrochlorothiazide ( 7.3 ): • Antidiabetic drugs: Dosage adjustment of antidiabetic may be required. (bula de Olmesartana + anlodipino + hidroclorotiazida, Interações medicamentosas)

Blood pressure should be closely monitored when amlodipine is co-administered with CYP3A inducers. (bula de Olmesartana + anlodipino + hidroclorotiazida, Interações medicamentosas)

Blood pressure should be closely monitored when amlodipine is co-administered with CYP3A inducers. (bula de Olmesartana + anlodipino + hidroclorotiazida, Interações medicamentosas)

Blood pressure should be closely monitored when amlodipine is co-administered with CYP3A inducers. (bula de Olmesartana + anlodipino + hidroclorotiazida, Interações medicamentosas)

Consider the potential for symptomatic hypotension or ischemia in patients with hypovolemia, severe left ventricular outflow obstruction, resting hypotension, autonomic dysfunction, or concomitant treatment with antihypertensives or strong CYP and P-gp/BCRP inhibitors [see Drug Interactions (7.2) and Clinical Pharmacology (12.3) ] . (bula de Riociguate, Advertências e precauções)

Clinically significant hypotension has been observed with concomitant use of oral RISPERDAL and antihypertensive medication. (bula de Risperidona, Advertências e precauções)

Immunosuppressants: Amlodipine may increase the systemic exposure of cyclosporine or tacrolimus when co-administered. (bula de Olmesartana + anlodipino + hidroclorotiazida, Interações medicamentosas)

• Increased amlodipine exposure when coadministered with CYP3A inhibitors Hydrochlorothiazide ( 7.3 ): • Antidiabetic drugs: Dosage adjustment of antidiabetic may be required. (bula de Olmesartana + anlodipino + hidroclorotiazida, Interações medicamentosas)

Immunosuppressants: Amlodipine may increase the systemic exposure of cyclosporine or tacrolimus when co-administered. (bula de Olmesartana + anlodipino + hidroclorotiazida, Interações medicamentosas)

Patients with an activated renin-angiotensin system, such as volume- and/or salt-depleted patients (e.g., those being treated with high doses of diuretics), are at greater risk. (bula de Sacubitril + valsartana, Advertências e precauções)

Diuretics: Use with caution. (bula de Salbutamol, Interações medicamentosas)

• Diuretics: Use with caution. (bula de Salmeterol, Interações medicamentosas)

Olmesartan medoxomil ( 7.1 ): • Nonsteroidal anti-inflammatory drugs (NSAIDS): May lead to increased risk of renal impairment and loss of antihypertensive effect. (bula de Olmesartana + anlodipino + hidroclorotiazida, Interações medicamentosas)

• Increased amlodipine exposure when coadministered with CYP3A inhibitors Hydrochlorothiazide ( 7.3 ): • Antidiabetic drugs: Dosage adjustment of antidiabetic may be required. (bula de Olmesartana + anlodipino + hidroclorotiazida, Interações medicamentosas)

• Increased amlodipine exposure when coadministered with CYP3A inhibitors Hydrochlorothiazide ( 7.3 ): • Antidiabetic drugs: Dosage adjustment of antidiabetic may be required. (bula de Olmesartana + anlodipino + hidroclorotiazida, Interações medicamentosas)

Immunosuppressants: Amlodipine may increase the systemic exposure of cyclosporine or tacrolimus when co-administered. (bula de Olmesartana + anlodipino + hidroclorotiazida, Interações medicamentosas)

• Increased amlodipine exposure when coadministered with CYP3A inhibitors Hydrochlorothiazide ( 7.3 ): • Antidiabetic drugs: Dosage adjustment of antidiabetic may be required. (bula de Olmesartana + anlodipino + hidroclorotiazida, Interações medicamentosas)

Elderly patients, patients taking diuretics, and those who are volume-depleted may be at greater risk of developing hyponatremia with SSRIs [see Use in Specific Populations ( 8.5 )] . (bula de Sertralina, Advertências e precauções)

Calcium antagonists Sevoflurane may lead to marked hypotension in patients treated with calcium antagonists. (bula de Sevoflurano, Interações medicamentosas)

When amlodipine, 5 mg or 10 mg, and sildenafil 100 mg were orally administered concomitantly to hypertensive patients, mean additional blood pressure reductions of 8 mmHg systolic and 7 mmHg diastolic were noted [see Drug Interactions ( 7.3 ) and Clinical Pharmacology ( 12.2 ) ]. (bula de Sildenafila, Advertências e precauções)

However, patients in the Phase 3 clinical studies taking concomitant antihypertensive medications with silodosin capsules did not experience a significant increase in the incidence of syncope, dizziness, or orthostasis. (bula de Silodosina, Advertências e precauções)

Drug Interactions with Amlodipine Simvastatin: Co-administration of simvastatin with amlodipine increases the systemic exposure of simvastatin. (bula de Olmesartana + anlodipino + hidroclorotiazida, Interações medicamentosas)

Immunosuppressants: Amlodipine may increase the systemic exposure of cyclosporine or tacrolimus when co-administered. (bula de Olmesartana + anlodipino + hidroclorotiazida, Interações medicamentosas)

• Increased amlodipine exposure when coadministered with CYP3A inhibitors Hydrochlorothiazide ( 7.3 ): • Antidiabetic drugs: Dosage adjustment of antidiabetic may be required. (bula de Olmesartana + anlodipino + hidroclorotiazida, Interações medicamentosas)

• Increased amlodipine exposure when coadministered with CYP3A inhibitors Hydrochlorothiazide ( 7.3 ): • Antidiabetic drugs: Dosage adjustment of antidiabetic may be required. (bula de Olmesartana + anlodipino + hidroclorotiazida, Interações medicamentosas)

Consider temporary or permanent discontinuation for severe or persistent hypertension despite antihypertensive therapy. (bula de Sorafenibe, Advertências e precauções)

Special attention should be given to electrolyte and acid-base balance in patients experiencing severe or prolonged diarrhea or patients receiving concomitant diuretic drugs. (bula de Sotalol, Advertências e precauções)

Olmesartan medoxomil ( 7.1 ): • Nonsteroidal anti-inflammatory drugs (NSAIDS): May lead to increased risk of renal impairment and loss of antihypertensive effect. (bula de Olmesartana + anlodipino + hidroclorotiazida, Interações medicamentosas)

Olmesartan medoxomil ( 7.1 ): • Nonsteroidal anti-inflammatory drugs (NSAIDS): May lead to increased risk of renal impairment and loss of antihypertensive effect. (bula de Olmesartana + anlodipino + hidroclorotiazida, Interações medicamentosas)

Initiate and/or adjust antihypertensive therapy as appropriate. (bula de Sunitinibe, Advertências e precauções)

• Increased amlodipine exposure when coadministered with CYP3A inhibitors Hydrochlorothiazide ( 7.3 ): • Antidiabetic drugs: Dosage adjustment of antidiabetic may be required. (bula de Olmesartana + anlodipino + hidroclorotiazida, Interações medicamentosas)

Prolonged Neuromuscular Block in Patients with Hypokalemia or Hypocalcemia Neuromuscular blockade may be prolonged in patients with hypokalemia (e.g., after severe vomiting, diarrhea, digitalisation and diuretic therapy) or hypocalcemia (e.g., after massive transfusions). (bula de Suxametônio (succinilcolina), Advertências e precauções)

Blood pressure should be closely monitored when amlodipine is co-administered with CYP3A inducers. (bula de Olmesartana + anlodipino + hidroclorotiazida, Interações medicamentosas)

• Increased exposure to cyclosporin and tacrolimus. (bula de Olmesartana + anlodipino + hidroclorotiazida, Interações medicamentosas)

…use of skeletal muscle relaxants and opioids, consider prescribing naloxone for the emergency treatment of opioid overdose [see Dosage and Administration (2.2) , Warnings and Precautions (5.2 , 5.3) ] Examples: cyclobenzaprine, metaxalone Diuretics Clinical Impact: Opioids can reduce the efficacy of diuretics by inducing the release of antidiuretic hormone. (bula de Tapentadol, Interações medicamentosas)

Hypotension In patients with an activated renin-angiotensin system, such as volume- or salt-depleted patients (e.g., those being treated with high doses of diuretics), symptomatic hypotension may occur after initiation of therapy with telmisartan tablets. (bula de Telmisartana, Advertências e precauções)

Simvastatin: Co-administration of multiple doses of 10 mg of amlodipine with 80 mg simvastatin resulted in a 77% increase in exposure to simvastatin compared to simvastatin alone. (bula de Telmisartana + anlodipino, Interações medicamentosas)

…Metabolic Disorders Drugs, including telmisartan, that inhibit the renin-angiotensin system can cause hyperkalemia, particularly in patients with renal insufficiency, diabetes, or combination use with other angiotensin receptor blockers or ACE inhibitors and the concomitant use of other drugs that raise serum potassium levels [see Drug Interactions (7.1 , 7.4) ] . (bula de Telmisartana + hidroclorotiazida, Advertências e precauções)

Monitor patients for signs and symptoms of angioedema when temsirolimus is given concomitantly with angiotensin converting enzyme (ACE) inhibitors (e.g., ramipril) or calcium channel blockers (CCB) (e.g., amlodipine). (bula de Tensirolimo, Interações medicamentosas)

Risk of Hypotension with Concomitant Use of Other Antihypertensive Agents and Phospodiesterase Type 5 Inhibitors (PDE5-I): Concomitant administration of TEZRULY with antihypertensives or phosphodiesterase-5 (PDE-5) inhibitors can result in additive blood pressure lowering effects and symptomatic hypotension (5.3). (bula de Terazosina, Advertências e precauções)

Diuretics The ECG changes and/or hypokalemia that may result from the administration of non-potassium sparing diuretics (such as loop or thiazide diuretics) can be acutely worsened by beta-agonists, especially when the recommended dose of the beta-agonist is exceeded. (bula de Terbutalina, Precauções)

Immunosuppressants: Amlodipine may increase the systemic exposure of cyclosporine or tacrolimus when co-administered. (bula de Olmesartana + anlodipino + hidroclorotiazida, Interações medicamentosas)

In patients with hypertension on antihypertensive therapy, TLANDO increased the mean systolic/diastolic BP by 4.8/1.6 mm Hg from baseline. [see Adverse Reactions ( 6.1 )] . (bula de Testosterona, Advertências e precauções)

• Increased amlodipine exposure when coadministered with CYP3A inhibitors Hydrochlorothiazide ( 7.3 ): • Antidiabetic drugs: Dosage adjustment of antidiabetic may be required. (bula de Olmesartana + anlodipino + hidroclorotiazida, Interações medicamentosas)

Oral or intravenous calcium antagonists may cause atrioventricular conduction disturbances, left ventricular failure, and hypotension. (bula de Timolol, Interações medicamentosas)

• Increased amlodipine exposure when coadministered with CYP3A inhibitors Hydrochlorothiazide ( 7.3 ): • Antidiabetic drugs: Dosage adjustment of antidiabetic may be required. (bula de Olmesartana + anlodipino + hidroclorotiazida, Interações medicamentosas)

Some diuretics can enhance aminoglycoside toxicity by altering antibiotic concentrations in serum and tissue. (bula de Tobramicina, Interações medicamentosas)

Immunosuppressants: Amlodipine may increase the systemic exposure of cyclosporine or tacrolimus when co-administered. (bula de Olmesartana + anlodipino + hidroclorotiazida, Interações medicamentosas)

Immunosuppressants: Amlodipine may increase the systemic exposure of cyclosporine or tacrolimus when co-administered. (bula de Olmesartana + anlodipino + hidroclorotiazida, Interações medicamentosas)

Olmesartan medoxomil ( 7.1 ): • Nonsteroidal anti-inflammatory drugs (NSAIDS): May lead to increased risk of renal impairment and loss of antihypertensive effect. (bula de Olmesartana + anlodipino + hidroclorotiazida, Interações medicamentosas)

Co-administration of diuretics also increases the risk of too rapid correction of serum sodium and such patients should undergo close monitoring of serum sodium. (bula de Tolvaptana, Advertências e precauções)

Blood pressure should be closely monitored when amlodipine is co-administered with CYP3A inducers. (bula de Olmesartana + anlodipino + hidroclorotiazida, Interações medicamentosas)

In patients with an activated renin-angiotensin system, such as volume- and/or salt-depleted patients (e.g., those being treated with high doses of diuretics) symptomatic hypotension may be anticipated after initiation of treatment with olmesartan medoxomil. (bula de Olmesartana + anlodipino + hidroclorotiazida, Advertências e precauções)

Drugs that decrease renal calcium excretion, e.g., thiazide diuretics, may increase the risk of hypercalcemia in patients receiving FARESTON. (bula de Toremifeno, Interações medicamentosas)

Diuretics Clinical Impact: Opioids can reduce the efficacy of diuretics by inducing the release of antidiuretic hormone. (bula de Tramadol, Interações medicamentosas)

Diuretics Clinical Impact: Opioids can reduce the efficacy of diuretics by inducing the release of antidiuretic hormone. (bula de Tramadol + paracetamol, Interações medicamentosas)

In studies of ACE inhibitors in patients with unilateral or bilateral renal artery stenosis, increases in serum creatinine or blood urea nitrogen (BUN) have been reported. (bula de Olmesartana + anlodipino + hidroclorotiazida, Advertências e precauções)

Concomitant use with an antihypertensive may require a reduction in the dose of the antihypertensive drug. (bula de Trazodona, Advertências e precauções)

In patients with an activated renin-angiotensin system, such as volume- and/or salt-depleted patients (e.g., those being treated with high doses of diuretics) symptomatic hypotension may be anticipated after initiation of treatment with olmesartan medoxomil. (bula de Olmesartana + anlodipino + hidroclorotiazida, Advertências e precauções)

In patients with an activated renin-angiotensin system, such as volume- and/or salt-depleted patients (e.g., those being treated with high doses of diuretics) symptomatic hypotension may be anticipated after initiation of treatment with olmesartan medoxomil. (bula de Olmesartana + anlodipino + hidroclorotiazida, Advertências e precauções)

Thiazide diuretics may accentuate the orthostatic hypotension that may occur with phenothiazines. (bula de Trifluoperazina, Precauções)

• Diuretics: Use with caution. (bula de Umeclidínio + vilanterol, Interações medicamentosas)

Immunosuppressants: Amlodipine may increase the systemic exposure of cyclosporine or tacrolimus when co-administered. (bula de Olmesartana + anlodipino + hidroclorotiazida, Interações medicamentosas)

Immunosuppressants: Amlodipine may increase the systemic exposure of cyclosporine or tacrolimus when co-administered. (bula de Olmesartana + anlodipino + hidroclorotiazida, Interações medicamentosas)

In patients with an activated renin-angiotensin system, such as volume- and/or salt-depleted patients receiving high doses of diuretics, symptomatic hypotension may occur. (bula de Valsartana, Advertências e precauções)

Vardenafil hydrochloride tablets can potentiate the hypotensive effects of nitrates, alpha- blockers, and antihypertensives. (bula de Vardenafila, Interações medicamentosas)

…propranolol, terbinafine, thiabendazole, ticlopidine, verapamil, zileuton montelukast, moricizine, omeprazole, phenobarbital, phenytoin, cigarette smoking CYP3A4 alprazolam, amiodarone, amlodipine, amprenavir, aprepitant, atorvastatin, atazanavir, bicalutamide, cilostazol, cimetidine, ciprofloxacin, clarithromycin, conivaptan, cyclosporine, darunavir/ritonavir, diltiazem,… (bula de Varfarina, Interações medicamentosas)

Also, patients taking diuretics or who are otherwise volume-depleted may be at greater risk [see Use in Specific Populations ( 8.5 )] . (bula de Venlafaxina, Advertências e precauções)

• Increased amlodipine exposure when coadministered with CYP3A inhibitors Hydrochlorothiazide ( 7.3 ): • Antidiabetic drugs: Dosage adjustment of antidiabetic may be required. (bula de Olmesartana + anlodipino + hidroclorotiazida, Interações medicamentosas)

Elderly patients, patients taking diuretics, and those who are volume-depleted may be at greater risk of developing hyponatremia with SSRIs and SNRIs [see Use in Specific Populations ( 8.5 )] . (bula de Vilazodona, Advertências e precauções)

Os diuréticos tiazídicos reduzem a excreção de cálcio; combinado com suplementos de vitamina D e de cálcio, isso pode levar a hipercalcemia, especialmente em idosos. (NIH Office of Dietary Supplements, Vitamin D)

• Increased amlodipine exposure when coadministered with CYP3A inhibitors Hydrochlorothiazide ( 7.3 ): • Antidiabetic drugs: Dosage adjustment of antidiabetic may be required. (bula de Olmesartana + anlodipino + hidroclorotiazida, Interações medicamentosas)

Also, patients taking diuretics or who are otherwise volume-depleted can be at greater risk. (bula de Vortioxetina, Advertências e precauções)

Hypokalemia may result from diuretic therapy, diarrhea, and other causes. (bula de Ziprasidona, Advertências e precauções)

Effects of Adenosine on Other Drugs Adenosine injection has been given with other cardioactive drugs (such as beta adrenergic blocking agents, cardiac glycosides, and calcium channel blockers) without apparent adverse interactions, but its effectiveness with these agents has not been systematically evaluated. (bula de Adenosina, Interações medicamentosas)

Coadministration of 1 Dyazide (triamterene/hydrochlorothiazide) resulted in a higher plasma amantadine hydrochloride concentration in a 61-year old man receiving amantadine hydrochloride 100 mg TID for Parkinson's disease. (bula de Amantadina, Interações medicamentosas)

Patients required intervention with a diuretic, fluid management, or, in some cases, hospitalization for decompensating heart failure. (bula de Ambrisentana, Advertências e precauções)

Corticosteroids, ACTH: Intensified electrolyte depletion, particularly hypokalemia. (bula de Olmesartana + anlodipino + hidroclorotiazida, Interações medicamentosas)

Corticosteroids, ACTH: Intensified electrolyte depletion, particularly hypokalemia. (bula de Olmesartana + anlodipino + hidroclorotiazida, Interações medicamentosas)

Corticosteroids, ACTH: Intensified electrolyte depletion, particularly hypokalemia. (bula de Olmesartana + anlodipino + hidroclorotiazida, Interações medicamentosas)

Corticosteroids, ACTH: Intensified electrolyte depletion, particularly hypokalemia. (bula de Olmesartana + anlodipino + hidroclorotiazida, Interações medicamentosas)

In such cases, butorphanol should be discontinued and the hypertension treated with antihypertensive drugs. (bula de Butorfanol, Advertências)

Os diuréticos tiazídicos reduzem a excreção de cálcio, de modo que um consumo alto de cálcio pode elevar o cálcio no sangue. (NIH Office of Dietary Supplements, Calcium)

Most epidemiologic studies examining fetal abnormalities after exposure to antihypertensive use in the first trimester have not distinguished drugs affecting the renin-angiotensin system from other antihypertensive agents. (bula de Candesartana + hidroclorotiazida, Advertências)

Corticosteroids, ACTH: Intensified electrolyte depletion, particularly hypokalemia. (bula de Olmesartana + anlodipino + hidroclorotiazida, Interações medicamentosas)

Corticosteroids, ACTH: Intensified electrolyte depletion, particularly hypokalemia. (bula de Olmesartana + anlodipino + hidroclorotiazida, Interações medicamentosas)

Renin-angiotensin-aldosterone Inhibitors Drugs that inhibit the renin-angiotensin-aldosterone system (RAAS) including angiotensin converting enzyme (ACE) inhibitors, angiotensin receptor blockers (ARBs), spironolactone, eplerenone, or aliskiren produce potassium retention by inhibiting aldosterone production. (bula de Cloreto de potássio, Interações medicamentosas)

Acthar Gel may accentuate the electrolyte loss associated with diuretic therapy. (bula de Corticotropina, Interações medicamentosas)

Fluid retention events were typically managed by supportive care measures that may include diuretics or short courses of steroids. (bula de Dasatinibe, Advertências e precauções)

Corticosteroids, ACTH: Intensified electrolyte depletion, particularly hypokalemia. (bula de Olmesartana + anlodipino + hidroclorotiazida, Interações medicamentosas)

…malignant hyperthermia in patients with known or suspected susceptibility based on genetic factors or family history, including those with certain inherited ryanodine receptor (RYR1) or dihydropyridine receptor (CACNA1S) variants. [see Contraindications (4), Clinical Pharmacology (12.5)] Signs consistent with malignant hyperthermia may include hyperthermia, hypoxia,… (bula de Desflurano, Advertências e precauções)

If other contraceptive methods are not suitable, hormonal contraceptive therapy may continue combined with antihypertensive therapy. (bula de Desogestrel + etinilestradiol, Advertências)

Corticosteroids, ACTH: Intensified electrolyte depletion, particularly hypokalemia. (bula de Olmesartana + anlodipino + hidroclorotiazida, Interações medicamentosas)

Examples of alkalinizing agents include gastrointestinal alkalinizing agents (e.g., sodium bicarbonate) and urinary alkalinizing agents (e.g. acetazolamide, some thiazides). (bula de Dextroanfetamina, Interações medicamentosas)

Patients developing peripheral edema may be treated with standard measures, e.g., salt restriction, oral diuretic(s). (bula de Docetaxel, Advertências e precauções)

Examples: α-adrenergic antagonists, β-adrenergic receptor antagonists, reserpine, quinidine, mephentermine Other Drug Interactions G u anethidine C linical Impact: Ephedrine may inhibit the neuron blockage produced by guanethidine, resulting in loss of antihypertensive effectiveness. (bula de Efedrina, Interações medicamentosas)

In addition to discontinuation of the drug, diuretic therapy may be required. (bula de Estrogênios esterificados + metiltestosterona, Advertências)

In Vivo Drug Interaction Studies Based on drug interaction studies in healthy patients, ULORIC does not have clinically significant interactions with colchicine, naproxen, indomethacin, hydrochlorothiazide, warfarin or desipramine [see Clinical Pharmacology (12.3) ]. (bula de Febuxostate, Interações medicamentosas)

…studies with acetaminophen, acetylsalicylic acid, α-blockers, angiotensin-converting enzyme (ACE) inhibitors, analgesics, anti-convulsants, beta-adrenergic blocking agents, diuretics, calcium channel blockers, cardiac nitrates, HMG-CoA reductase inhibitors, nonsteroidal anti-inflammatory drugs (NSAIDs), benzodiazepines, H 2 antagonists and quinolone anti-infectives… (bula de Finasterida, Interações medicamentosas)

Flecainide acetate has been used in a large number of patients receiving diuretics without apparent interaction. (bula de Flecainida, Interações medicamentosas)

Corticosteroids, ACTH: Intensified electrolyte depletion, particularly hypokalemia. (bula de Olmesartana + anlodipino + hidroclorotiazida, Interações medicamentosas)

Corticosteroids, ACTH: Intensified electrolyte depletion, particularly hypokalemia. (bula de Olmesartana + anlodipino + hidroclorotiazida, Interações medicamentosas)

Corticosteroids, ACTH: Intensified electrolyte depletion, particularly hypokalemia. (bula de Olmesartana + anlodipino + hidroclorotiazida, Interações medicamentosas)

Corticosteroids, ACTH: Intensified electrolyte depletion, particularly hypokalemia. (bula de Olmesartana + anlodipino + hidroclorotiazida, Interações medicamentosas)

When other potent parenteral antihypertensive drugs, such as diazoxide, are used in combination with hydralazine, patients should be continuously observed for several hours for any excessive fall in blood pressure. (bula de Hidralazina, Interações medicamentosas)

Corticosteroids, ACTH: Intensified electrolyte depletion, particularly hypokalemia. (bula de Olmesartana + anlodipino + hidroclorotiazida, Interações medicamentosas)

ACE Inhibitors FIRAZYR is a bradykinin B2 receptor antagonist and thereby has the potential to have a pharmacodynamic interaction with ACE inhibitors where FIRAZYR may attenuate the antihypertensive effect of ACE inhibitors. (bula de Icatibanto, Interações medicamentosas)

Hydrochlorothiazide: A study in normal healthy volunteers has shown that concomitant administration of isradipine and hydrochlorothiazide does not result in altered pharmacokinetics of either drug. (bula de Isradipino, Interações medicamentosas)

Postmarketing cases of edema and fluid retention occurring within weeks of starting OPSUMIT, some requiring intervention with a diuretic or hospitalization for decompensated heart failure, have been reported [see Adverse Reactions (6.2) ] . (bula de Macitentana, Advertências e precauções)

O uso prolongado de diuréticos de alça e tiazídicos aumenta a perda de magnésio na urina. (NIH Office of Dietary Supplements, Magnesium)

Drug Interactions When methyldopa is used with other antihypertensive drugs, potentiation of antihypertensive effect may occur. (bula de Metildopa, Interações medicamentosas)

Corticosteroids, ACTH: Intensified electrolyte depletion, particularly hypokalemia. (bula de Olmesartana + anlodipino + hidroclorotiazida, Interações medicamentosas)

In addition to discontinuation of the drug, diuretic therapy may be required. (bula de Metiltestosterona, Advertências)

In a large compassionate use program mexiletine has been used concurrently with commonly employed antianginal, antihypertensive, and anticoagulant drugs without observed interactions. (bula de Mexiletina, Interações medicamentosas)

…been observed in limited experience with patients in whom milrinone was used concurrently with the following drugs: digitalis glycosides; lidocaine, quinidine; hydralazine, prazosin; isosorbide dinitrate, nitroglycerin; chlorthalidone, furosemide, hydrochlorothiazide, spironolactone; captopril; heparin, warfarin, diazepam, insulin; and potassium supplements. (bula de Milrinona, Interações medicamentosas)

Corticosteroids, ACTH: Intensified electrolyte depletion, particularly hypokalemia. (bula de Olmesartana + anlodipino + hidroclorotiazida, Interações medicamentosas)

The blood pressure effect of SULAR tended to be greater in patients on atenolol than in patients on no other antihypertensive therapy. (bula de Nisoldipino, Interações medicamentosas)

Hypertensive patients, and patients concomitantly receiving other antihypertensive medications, may be more sensitive to the effects of sodium nitroprusside than normal subjects. (bula de Nitroprusseto de sódio, Advertências)

The antihypertensive action of guanethidine and similar agents may be blocked. (bula de Nortriptilina, Advertências)

Corticosteroids, ACTH: Intensified electrolyte depletion, particularly hypokalemia. (bula de Olmesartana + anlodipino + hidroclorotiazida, Interações medicamentosas)

Corticosteroids, ACTH: Intensified electrolyte depletion, particularly hypokalemia. (bula de Olmesartana + anlodipino + hidroclorotiazida, Interações medicamentosas)

Corticosteroids, ACTH: Intensified electrolyte depletion, particularly hypokalemia. (bula de Olmesartana + anlodipino + hidroclorotiazida, Interações medicamentosas)

Protriptyline may block the antihypertensive effect of guanethidine or similarly acting compounds. (bula de Protriptilina, Advertências)

There is no information available from adequate drug-drug interaction studies with the following classes of drugs: oral contraceptives, hormone replacement therapies, hypoglycemics, phenytoins, thiazide diuretics, and calcium channel blockers. (bula de Terbinafina, Interações medicamentosas)

Corticosteroids, ACTH: Intensified electrolyte depletion, particularly hypokalemia. (bula de Olmesartana + anlodipino + hidroclorotiazida, Interações medicamentosas)

No other formal drug-drug interaction studies between zafirlukast and marketed drugs known to be metabolized by the P450 3A4 (CYP3A4) isoenzyme (e.g., dihydropyridine calcium-channel blockers, cyclosporin, cisapride) have been conducted. (bula de Zafirlucaste, Precauções)

Os diuréticos tiazídicos aumentam a perda de zinco na urina com o uso prolongado. (NIH Office of Dietary Supplements, Zinc)

Calcium channel blocking agents: Coadministration of calcium channel blockers did not have any effect on either the safety or efficacy of ibutilide in the clinical trials. (bula de Ibutilida, Interações medicamentosas)

Loop Diuretics Concomitant administration of a loop diuretic had no effect on the calcium-lowering action of pamidronate disodium. (bula de Pamidronato, Interações medicamentosas)

Commonly Administered Drugs: Population analysis showed that commonly administered drugs (e.g., selegiline, amantadine, tricyclic antidepressants, benzodiazepines, ibuprofen, thiazides, antihistamines, anticholinergics) did not affect the clearance of ropinirole. (bula de Ropinirol, Interações medicamentosas)